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Abstract 
Substituted indoles (2-arylindoles) and related structures are known to exhibit 
potent anti-cancer activity against human breast cancer cell lines, and a range of other 
therapeutic targets. This activity, and other factors such as their biological activity, the fact 
that they are privileged structures, and the presence of the indole nucleus in various 
commercial anti-cancer drugs led to the choosing of indoles for the current study as a 
starting point for the development of new treatments against glioma. Investigation began on 
determining the anti-cancer activity of a variety of indoles against glioma cell lines 
(1321N1 and U87MG) using a number of different cell-based assays and also to compare 
them with conventional anti-cancer drugs. The aim was to find potent anti-cancer 
compound(s), amongst the compounds tested, and by studying its preliminary structure-
activity-relationships (SAR), try to determine how the active compound(s) may be exerting 
their effects. 
 The SAR screening was divided into two main groups: indoles without a 2-aryl 
group and indoles with a 2-aryl group. The most potent compound identified, and its 
analogues, were further tested on the non-cancerous SVGp12 cell line to check for 
specificity of these indoles towards cancer cells, wherein it was found that these 
compounds were not specific to any particular cell type. Furthermore, activity was also 
observed for the best lead compound in the glioblastoma short-term culture, IN859, in 
which it gave a relatively low micromolar IC50 value (400 μM). 
The results indicated that the anti-cancer activity of these compounds started within 
2 h and therefore it was speculated that the mechanism of action of these compounds might 
work through the generation of reactive oxygen species (ROS). A ROS-detection kit was 
used to demonstrate this hypothesis, a result which was later corroborated using flow 
cytometry, and also provided quantitative analysis of the amount of ROS generated. It was 
further hypothesised that in the cells studied, autophagy was mediated due to excessive 
ROS generation. This was also confirmed over a similar time course by quantifying the 
amount of fluorescence generated in the 1321N1 and U87MG cell lines when labelled with 
acridine orange (a dye used to detect the formation of autophagosomes during autophagy) 
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using flow cytometry. Moreover, the use of an autophagy inhibitor, 3-methyladenine, was 
shown to inhibit autophagy in these cell lines, again validating this hypothesis. 
 In conclusion, it has been demonstrated that the ability of certain substituted 
privileged indoles possessing a 2-aryl group and having an attached –OH group to it may 
have a rapid, deleterious effect on the viability of a primary short term culture (IN859) and 
glioma cell lines (1321N1 and U87MG). The mechanism of action of these indoles to cause 
cell death may be via the generation of ROS, leading to cell death initiated by autophagy. 
Another short separate study was also performed in order to investigate the anti-
cancer activity of an anionic host defence peptide, Cn-AMP2, on the above mentioned cell 
lines. This peptide was found to exhibit a modest cytostatic effect on both the cell lines but 
at higher concentrations (> 1 mM) and only when the serum concentrations were weaned 
down from 10 % to 2.5 %. 
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1.INTRODUCTION 
1.1 Brain tumours 
Brain tumours are masses or growths of abnormal cells in the brain and are typically 
categorised as either primary or secondary. Those which originate in the brain are called 
primary tumours while secondary tumours are formed when cancer cells from body parts 
such as lung or breast, spread to the brain (Aminoff, 2011). 
 
Figure 1: Coloured computed tomography (CT) brain scan showing a large intracranial tumour, the large 
round mass (green) seen at centre.  Within the tumour, spots indicate fluid-filled cysts (Image available at 
https://sciencephoto.com/media/254804/view). 
Primary brain tumours can be non-cancerous (benign) or cancerous (malignant) and 
are less common compared to secondary brain tumours. However, unlike cancers elsewhere 
in the body, primary malignant brain tumours rarely spread from the brain. Primary 
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tumours are mostly benign which means that they remain located in the area where they 
originated and do not spread to the other parts of the body. Benign tumours can be operated 
upon and taken out completely and if successful they do not cause any further problems. 
Successful removal of a benign tumour also depends upon the location of the tumour. 
Sometimes it is difficult to remove benign tumours as doing so might damage the 
surrounding sensitive brain cells (Aminoff, 2011). 
Malignant brain tumours grow more rapidly than benign tumours and destroy 
surrounding brain cells. A brain tumour, primary or secondary, can cause a variety of signs 
and symptoms because it can directly press on or invade brain tissue (Figure 1). The signs 
and symptoms include severe headaches, difficulties with balancing, personality or 
behavioural changes, hearing problems, vision problems including blurred vision, double or 
loss of peripheral vision (Aminoff, 2011). 
1.1.1 Glioma 
Brain tumours arising from the glial cells in the brain are known as gliomas. 
Gliomas are a heterogeneous group of neoplasms and comprise the majority of tumours 
which originate in the central nervous system (CNS) (Burton and Prados, 2000). Glial cells 
are the most common cells in the brain and their important functions include supporting and 
protecting the nerve cells, supplying energy and nutrients and maintaining the blood- brain 
barrier (BBB). Each type of glial cell has its own independent function, for example, 
astrocytes help in the transportation of nutrients and help in supporting neurons in place, 
oligodendrocytes provide insulation to the neurons, microglia digest dead neurons and 
pathogens and ependymal cells line the ventricles and also secrete cerebrospinal fluid 
(Louis et al., 2001). 
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Gliomas are comprised of a mix of neoplastic and non-neoplastic cells, which 
include native and recruited cells and there is a vast diversity among the tumour cells with 
respect to in vitro growth, a key property for cell differentiation. Tumourigenic cells, which 
are undifferentiated and have the capacity for developing into tumours, are termed stem 
cells (Park and Rich, 2009). Gliomas vary in their aggressiveness, or malignancy and as 
such, there is a gradation of gliomas, which is based on how normal or abnormal the 
tumour cells appear when examined under a microscope. Glioma cases are mostly observed 
in industrial and developed countries and among them, glioblastoma is the most frequent 
and malignant histological type (Fisher et al., 2007). It is very important to study the 
genomic conditions along with the continued evaluation of environmental and development 
factors for gliomas. To achieve this goal, large sample sizes and multidisciplinary teams 
with expertise in neuropathology, genetics, epidemiology, functional genomics, 
bioinformatics, biostatistics, immunology and neuro-oncology are required, all of which 
can help to explore relevant pathways and the modifying effects of other genes, to avoid 
false positive findings (Fisher et al., 2007). 
1.1.1.1 Epidemiology of glioma 
Brain tumours are one of the most devastating forms of cancer and are the second 
leading cause of death in men and children and the fifth leading cause of death in women 
(Jemal et al., 2010). The worldwide annual incidence rate of primary malignant brain 
tumours ranges from 5.8 per 100,000 for males and 4.1 per 100,000 for females in 
developed countries (Jain et al., 2008; Schwartzbaum et al., 2006).  In 2008, 4,785 people 
in Europe were diagnosed with malignant brain tumours with 4,552 people being diagnosed 
with other non-invasive types of brain tumour (Crocetti et al., 2012). The rate of incidence 
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of primary brain tumour in the US increases steadily with increase in age, which peaks at 
65.5/100,000 person years (ABTA, 2010). Gliomas account for 86 % of primary tumours 
and strongly influence the statistical data for primary tumours in the UK (McKinney, 
2004). The incidence of primary tumours also shows a variation with sex, race, age and 
geography (Moore and Kim, 2010), and approximately 13,000 deaths and 18,000 new cases 
of primary malignant brain and CNS tumours occur annually in the US (Schwartzbaum et 
al., 2006). About 4,500 new cases of glioma occur every year in the UK, of which 20 % are 
low grade gliomas and the remaining 80 % are high grade gliomas (Efird, 2011). In Europe, 
cases of primary brain tumour comprising of high grade glioma and brain metastasis 
observed range from 4.5 to 11.2 cases per 100,000 in men and from 1.6 to 8.5 per 100,000 
in women (Crocetti et al., 2012). 
 
 
 
 
 
 
 
 
Figure 2: Data provided in the graph are for adults aged 15-99 diagnosed in England and Wales which 
predicts the survival estimates. Brain tumour shows insignificant increase in the median survival rate over 
three decades (Rachet et al., 2009). 
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A report by Macmillan Cancer Support stated that over the past three decades, brain 
tumour treatment has not led to an increase in the survival period of brain tumour patients 
(Figure 2) (Rachet et al., 2009). The survival of glioma patients is still poor, with pilocytic 
astrocytoma being an exception. The 5-year survival rate of glioblastoma patients is less 
than 3 % (Burkhard et al., 2003), and a number of epidemiological studies have revealed 
that certain occupations have an increased brain tumour risk. However, no epidemiological 
analyses have led to identification of an environmental carcinogen that could be 
unequivocally linked to brain tumour development (Ohgaki and Kleihues, 2005). 
1.1.1.2 Classification 
Based on presumed cell origin, gliomas are classified as astrocytic, oligodendrocytic 
and mixed gliomas (Louis et al., 2001). The following criteria are used for grading: 
increase in cellular density, nuclear atypias, mitosis, vascular proliferation and necrosis. 
Pilocytic astrocytomas are benign and are classified as grade I gliomas. Low-grade (II) or 
high-grade tumours (III and IV) are diffuse astrocytomas, oligodendrogliomas and 
oligoastrocytomas, while glioblastomas are grade IV astrocytomas (Louis et al., 2007). 
Several molecular genetic alterations have been characterised in gliomas in the past years. 
Molecular profiles have been associated with specific histological and prognostic tumour 
subgroups, contributing to improve the classification of gliomas. At least two alternative 
molecular pathways have been suggested in the astrocytoma progression involving TP53 
inactivation (secondary glioblastomas) and EGFR amplification (de novo glioblastomas) 
(Frankel et al., 1992; Biernat et al., 1995). Oligodendroglial tumours have demonstrated 
recurrent combined loss of chromosome 1p/19q, which represent a favourable prognosis 
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marker and probably a predictor of a good chemosensitivity of the tumour (Hoang-Xuan et 
al., 2005). 
  In adults, the most frequently encountered tumours are high-grade or malignant 
neoplasms of astrocytic and oligodendrocytic lineage (Burton and Prados, 2000). Malignant 
gliomas are the most common primary CNS tumours (Zhu et al., 2005) and in spite of 
intensive clinical investigation and many therapeutic approaches, the treatment for primary 
brain tumours remains inadequate (Kim and Glantz, 2006). The WHO system further 
grades these on the basis of histological degrees of malignancy with grade I being the least 
malignant to grade IV being the most malignant (Louis et al., 2001). Low-grade tumours 
(grade I and II) are usually circumscribed and grow slowly over a period of time while 
high-grade tumours (grade III and IV) are comparatively aggressive having poor prognosis. 
Some of the low-grade gliomas undergo malignant transformation to high-grade neoplasms 
with age, lifestyle and time. Glioblastoma multiforme (GBM) and anaplastic astrocytoma 
(AA) are the most malignant and aggressive high-grade gliomas (WHO grade IV and III 
respectively), having a combined incidence of 5-8/100,000 population (Koukourakis et al., 
2009). WHO revised the classification and added three new tumours in 2007: angiocentric 
glioma (AG), pilomyxoid astrocytoma (PMA) and pituicytoma (table 1) (Louis et al., 2007; 
Brat et al., 2007). 
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Table 1: WHO classification of glioma (Louis et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
  
1.1.1.3 Diagnosis of glioma 
Patients with malignant gliomas have to undergo tissue diagnosis to undertake 
further clinical management. The tumours are visualised by Magnetic Resonance Imaging 
(MRI) scanning using an intravenous contrast dye while the grade and type of tumour can 
be identified using magnetic resonance spectroscopy (MRS) (Shah et al., 2006). Optical 
methods like confocal imaging, multi-photon imaging and microscopic imaging are also 
being used in current cancer research. These imaging techniques usually do not validate the 
diagnosis with certainty, and therefore the gold standard for diagnosis is a brain biopsy. The 
microscopic appearance of biopsied tissue, with the help of special tissue stains, usually 
yields a definitive diagnosis (Nikiforova and Hamilton, 2011). Diagnosis of high-grade 
glioma is usually made through a Computed Tomography (CT) scan or MRI. With the help 
of a CT and MRI scan, the tumour can be detected as well obtaining information on size, 
location, morphology and spread of the tumour. The diagnosis is then established and the 
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tumour is classified histologically, either at the time of surgical resection or by a single-
event biopsy if surgery is not possible. There is a growing understanding of the molecular 
genetics of gliomas, which allows a more accurate classification of glioma to take place and 
may give an indication of prognosis and likely response to treatment. 
Glioblastoma multiforme is diagnosed by a fine needle aspiration biopsy (Schultz et 
al., 2005), whilst histological diagnosis of gliosarcoma is confirmed on the presence of 
tissue with gliomatous or mesenchymal differentiation as well as reticulin formation 
(Hoang-Xuan et al., 2005; Boerman et al., 1996; Reis et al., 2000). Oligodendroglioma is 
diagnosed histologically on the presence of mild to moderate glial neoplasms with no or 
low mitotic activity (Kleihues and Cavenee, 2000). Also, further research on the diagnosis 
of gliomas is being done by designing immunotherapeutic strategies based on 
pharmacogenomic findings (Yamanaka and Itoh, 2007).  
1.1.1.4 Treatments for glioma 
Gliomas are among the most common brain tumours leading to mortality, since they 
are difficult to treat. On diagnosis of glioma, the standard form of treatment consists of 
maximal surgical resection of the tumour, radiotherapy and concomitant and adjuvant 
chemotherapy. This treatment is standard because of major challenges like tumour 
heterogeneity, location of the tumour (as it can be beyond the reach of surgical 
intervention) and rapid, aggressive tumour relapse, therefore success of therapy depends on 
the grade of the tumour, extent of surgical tumour removal, location and age. Recurrent 
gliomas can be treated by surgery in appropriate patients, since low grade tumours are less 
likely to resurface, while older patients are treated with less aggressive therapy like 
radiation etc. Surgery cannot be used to treat glioma developed in the brain stem since it is 
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too delicate to be operated on (Barnet, 2007). High grade tumours are treated with surgery 
followed by radiotherapy as this treatment pattern helps to control the growth, spread and 
symptoms of the tumour. Long courses of radiotherapy are not suitable for patients who are 
not fit or do not take enough self-care, and these patients may be offered a short course of 
palliative radiotherapy or conformal radiotherapy in which the radiation beam is shaped to 
fit the tumour (Chang et al., 2005). 
Surgery and radiation continue to be the prime modalities of therapy for malignant 
brain tumours. However, chemotherapy is another option for the treatment of glioma, but 
the role of such a therapy in malignant gliomas has been inconclusive (Kim and Glantz, 
2006). Nevertheless, a phase II study of bevacizumab plus temozolomide (TMZ), during 
and after radiation therapy for patients with newly diagnosed glioblastoma multiforme, 
showed a significant survival benefit over radiation therapy alone (Lai et al., 2011). 
1.1.1.4.1 Surgery 
The role of surgery in the treatment of malignant gliomas includes establishing a 
pathological diagnosis, relief of mass effect, and cytoreduction (Laws et al., 2003; 
Rampling et al., 2004). The indications for surgical intervention can be divided into 
practical and theoretical considerations. The practical indications are: to obtain a 
histological diagnosis, given the lack of absolute specificity of modern radiographic 
imaging; to improve neurologic symptoms and/or signs in patients for whom the mass 
effect of their tumour, and its surrounding oedema, is a direct cause of disability; to delay 
the onset of new symptoms; and to improve survival by removing immediately life-
threatening lesions. Theoretical indications for surgical intervention are controversial but 
are generally thought to improve the patient's response to adjunctive or combination 
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chemotherapy and include removal of poorly oxygenated and radiation-resistant tumour 
cells, the removal of poorly vascularised regions of the tumour that are sequestered from 
systemic chemotherapy on the basis of marginal blood supply, and the overall reduction of 
tumour cells that have the potential to proliferate (DeAngelis et al., 2002). 
1.1.1.4.2 Radiation 
The most important achievement of radiation therapy is to specifically kill tumour 
cells in order to leave normal brain tissues unharmed (Shaw et al., 2006). Multiple 
treatments of standard-dose "fractions" of radiation are applied to the brain in a standard 
external beam radiation therapy. Unfortunately, each treatment leads to the destruction of 
the healthy as well as normal tissue. Until the next treatment, most of the normal cells have 
managed to repair any damage caused, while the tumour tissue is unable to repair the 
damage as quickly as the normal tissue. This particular procedure is repeated at least 10 to 
30 times depending on the type of tumour and such extra treatment gives some patients 
improved results and longer survival rates (Fisher et al., 1998). Even though survival in 
patients with malignant gliomas remains restricted, there is optimism with the emergence of 
such treatment strategies (Avgeropoulos and Batchelor, 1999). 
1.1.1.4.3 Chemotherapy 
Chemotherapy refers to drugs used for cancer treatment. Irrespective of treatment 
with surgery and radiotherapy, their unavoidable recurrence makes high-grade gliomas the 
most devastating neoplasms leading to death. Since the late 1970s, various randomised 
clinical trials have also tried to evaluate the role of adjuvant chemotherapy in the 
improvement of survival for glioma patients, but such studies still remain inconclusive 
(Lonardi et al., 2005). 
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Chemotherapy is a form of systemic treatment in which the drugs travel through the 
body to reach the cancer cells. There are numerous drugs which are used as 
chemotherapeutic agents to treat the many cancers which exist, and these drugs can be used 
alone or can be coupled and used in combination with other drugs or even other treatments 
(Sersa et al., 2008). 
Chemotherapy is a systemic treatment, unlike radiation and surgery which target the 
tumour directly, and hence these are termed local treatments. They act in one specific area 
like the breast, lung or prostate. Research on this subject is growing rapidly and more and 
more drugs are becoming available. For an anti-cancer drug to be effective, it must satisfy 
numerous features, such as: the drug must reach the cancer cells; sufficiently toxic amounts 
of drug (or its active metabolite) must enter the cells and remain there for a long enough 
period of time; the cancer cells must be sensitive to the effects of the drug, and all this must 
occur before resistance emerges (Galanis and Buckner, 2000). In addition the patient must 
be able to withstand the adverse effects of treatment. 
One of the first promising compounds identified as useful anti-cancer 
chemotherapeutic agents were the alkylating agents with their distinctive property of 
adding alkyl groups to the DNA in tumour cells, thus forming a variety of interstrand cross-
links (Espinosa et al., 2003). These adducts cause alterations in the DNA’s structure and 
interfere with DNA transcription and replication thus leading to growth inhibition of 
tumour cells (Schilsky, 1996). These drugs are most effective on rapidly proliferating cells 
and are independent of the mitotic rate of the tumour (Newton, 2006). Temozolomide, 
nitrosourea compounds, such as ACNU (nimustine), BCNU (carmustine), and CCNU 
(lomustine), have been successfully used as single agents as well as in various 
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combinations in the salvage treatment of gliomas as they are highly lipid soluble and 
readily cross the BBB. Conversely, cisplatin and carboplatin are platinum based drugs 
which are water-soluble alkylating (methylating) agents and are given via intra-arterial or 
intravenous routes (Bernstein and Berger, 2008). They cause DNA damage via intrastrand 
crosslink formation and chelation. Their penetration through the BBB is restricted due to 
their water soluble nature; cisplatin is almost never used on its own and is mostly given in 
combination with other drugs because of its toxic nature, which may result in renal failure, 
peripheral neuropathy and hearing loss (Brown, 2004). 
In the current study, privileged indoles were tested on various glioma cell lines. 
These indoles were tested in comparison with commercially used drugs so that the dosage 
and the minimum/maximum time for treatment could be estimated and compared. For that 
reason, various commercially available drugs such as cisplatin, temozolomide, gemcitabine, 
carmustine and etoposide were tested and compared on both the 1321N1 and U87MG 
glioma cell lines. 
1.2 Small molecules 
All the indoles screened in the current study have molecular weights lower than 351 
g/mol and therefore come under the category of small molecules according to the upper 
molecular weight limit (800 g/mol) for a compound to be termed a small molecule 
(Surhone et al., 2010). All the compounds tested in this study, excluding the antimicrobial 
peptide, follow one of the most important rules in drug development; Lipinski's “Rule of 
Five”. It is a well-established rule of thumb used to determine if a chemical compound with 
specific biological or pharmacological activity has certain properties that would make it an 
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orally active drug. This rule was formulated by Christopher A. Lipinski in 1997, based on 
the observation that most medicines are relatively small and lipophilic molecules (Lipinski 
et al., 2001). This rule describes the molecular properties which are important for a drug to 
possess suitable pharmacokinetics in the human body, including their absorption, 
distribution, metabolism, and excretion (ADME) (Lipinski et al., 2001). However, the rule 
does not predict if a compound is pharmacologically active. Lipinski's rule states that, in 
general, an orally active drug has no more than one violation of the following criteria: 
 Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or more 
hydrogen atoms attached) 
 Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
 A molecular mass less than 500 g/mol 
 An octanol-water partition coefficient, log P, not greater than 5 
The origin of the term “Rule of Five” is that all the numbers above are multiples of five. 
The rule is important for drug development where a pharmacologically active lead structure 
is optimised gradually for amplified activity and specificity, as well as drug-like properties 
such as lipophilicity, solubility, permeability, chemical and metabolic stability (Oprea et 
al., 2001). 
1.2.1 Indoles 
Indoles are natural compounds that are found in many plants, but particularly those 
associated with cruciferous vegetables such as broccoli, cauliflower, cabbage and Brussels 
sprouts. Indoles are of great interest to the pharmaceutical industry, and at the present time 
several thousand specific derivatives are reported annually. Chemically, indoles (Figure 3) 
Chapter I. Introduction 
 
 
15 
are aromatic heterocyclic organic compounds which contain an indole ring; a bicyclic 
structure, involving a six-membered benzene ring fused to a five-membered nitrogen-
containing pyrrole ring (Sundberg, 1996). 
 
Figure 3: Different representations of the chemical structure of  indole. 
1.2.1.1 History 
  The first preparation of indole dates from 1866  and certain indole derivatives were 
vital dyestuffs until the end of the 19th century. Indole chemistry started developing with 
the study of the dye indigo, and in 1866, Adolf von Baeyer reduced oxindole to indole 
using zinc dust and proposed a formula for the product (Figure 4) (Baeyer and Emmerling, 
1869). In the 1930s, interest in indole strengthened when it was identified that the indole 
nucleus is present in numerous alkaloids, tryptophan and auxins (VanOrder and Lindwall, 
1942). 
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Figure 4: Baeyer's original structure for indole (Baeyer and Emmerling, 1869). 
1.2.1.2 Synthesis 
Fischer’s indole synthesis remains the most versatile method for preparing indoles 
and was first reported in 1883 (Sumpter and Miller, 1954). The principal commercial 
source of indole is extraction from coal tar, even though the feasibility of industrial 
synthesis from starting materials such as aniline and ethylene glycol, N-ethylaniline or 2-
ethylaniline has been demonstrated (Sundberg, 1996). 
1.2.2 The importance of the indole motif in drug design 
Substituted indoles and related structures are known to exhibit potent anti-cancer 
activity against human breast cancer cell lines (Wang et al., 2006; Brew et al., 2009) and it 
has also been observed that indoles possess a wide range of biological activity in different 
therapeutic areas (Joshi and Chand, 1982). Moreover, various commercially available anti-
cancer drugs such as indole-3-carbinol (I3C), vinblastine, vincristine and sunitinib contain 
an indole ring, indicating that the indole nucleus may be one of the important subunits for 
the above mentioned compounds’ anti-tumour activities to exist. As a result, a considerable 
amount of research is currently taking place on numerous indole derivatives and their 
potential anti-cancer activities are being evaluated (Chao et al., 2007; Aronchik et al., 
2012; Nguyen et al., 2010). Having such precedent, in the current study it was decided to 
investigate the effects of structurally similar substituted indoles on human glioma cell lines 
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1321N1 and U87MG which act as models for glioma and which, to date, have not been 
extensively studied to ascertain their effects with indoles. Below are the key aspects which 
were considered when selecting indole derivatives as novel compounds to be used in this 
study. 
1.2.2.1 Biological activity 
The synthesis and reactivity of indole derivatives has been a topic of research 
importance for more than a century. The primary reason for this continued interest is the 
wide range of biological activity found among indoles (Joshi and Chand, 1982). For 
example, the indole ring appears in the amino acid tryptophan, and metabolites of 
tryptophan are vital in the biological chemistry of both animals and plants. 3-(2-
Aminoethyl)-5-hydroxyindole (serotonin) is the key neurotransmitter in animals (Osborne 
et al., 1982), while indole-3-acetic acid is the most abundant and basic auxin natively 
occurring and functioning in plants, generating the majority of auxin effects in intact plants 
(Sundberg, 1996). The indole nucleus is also found in several natural products such as the 
catharanthus alkaloids, which are well-established mitotic inhibitors (Brancale and 
Silvestri, 2007; De Martino et al., 2006; Jordan and Wilson, 2004), and the marine alkaloid 
eudistomin K, which has been shown to have an in vitro IC50 = 0.01 g/mL against the 
tumour P-388 mouse leukaemia cell line (Gul and Hamann, 2005; Lake et al., 1989).  
The search for specific agonists and antagonists of the receptors for these and other 
indole metabolites has been an active pursuit of pharmaceutical chemistry for nearly half a 
century, and not surprisingly, since the indole ring also appears in several natural products 
such as indole alkaloids (Southon and Buckingham, 1989), fungal metabolites (Horakova 
and Betina, 1977) and marine natural products which have potent biological activities 
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(Christophersen, 1983). The dimeric indole vinca alkaloid, vincristine, and closely related 
compounds, were among the first of the anti-mitotic class of chemotherapeutic agents for 
cancer (Brossi, 1992), and likewise, the anti-tumour antibiotic mitomycin C, which after 
bio-reductive activation, forms inter- and intra-strand cross-links with DNA, contains an 
oxidised indole nucleus (Tomasz, 1995).  
1.2.2.2 Indoles in cancer 
Privileged structures represent various classes of different molecules which are 
known to bind to multiple receptors with high affinity. As such, the study of these 
molecules in drug discovery is rapidly emerging in medicinal chemistry, especially since it 
is considered that such privileged structures could allow medicinal chemists to discover 
biologically active compounds, across a broad range of therapeutic areas, in a reasonable 
time scale (Horton et al., 2003). As alluded to above, one such class of privileged structures 
is the indole class, and because of its presence in a broad range of pharmacologically active 
molecules, it has been proposed that indoles possibly represent the most important of all 
structural classes in drug discovery (Horton et al., 2003; Joshi and Chand, 1982). As a 
result, it is predictable that the indole motif will have made its way into clinically useful 
drugs, and discussed below are the various commercially available drugs and indole 
derivatives currently being used/developed for the treatment of cancer. 
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1.2.2.2.1 Indole-3-carbinol 
 
Figure 5: Formation of indole-3-carbinol. (Available at 
http://lpi.oregonstate.edu/infocenter/phytochemicals/i3c/fig1.html). 
Indole-3-carbinol (I3C) is an alkaloid with an indole core, and it is found in some 
fruits and vegetables, including members of the cruciferous family and, in particular, 
members of the genus Brassica (Higdon et al., 2007). It is derived from the hydrolysis of 
glucobrassicin, a glucosinolate, which is predominant in brassica vegetables, it is 
synthesized from indole-3-glucosinolate by the action of the enzyme myrosinase 
(Verhoeven et al., 1997) (Figure 5). The stability of glucosinolates is heavily influenced by 
external factors and therefore the amount of I3C formed from glucobrassicin in foods is 
variable and relies on the processing and preparation of those foods. Its anti-tumour effects 
in experimental animals (Oganesian et al., 1997; Jin et al., 1999; Kojima et al., 1994) and 
humans (Wong et al., 1997; Yuan et al., 1999) are well documented, and previous studies 
have shown that I3C activates specific transcriptional factors, signal transduction, and 
metabolic cascades that lead to cell cycle arrest, apoptosis, down-regulation of cancer cell 
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migration, and modulation of hormone receptor signaling (Aggarwal and Ichikawa, 2005; 
Safe et al., 2008; Kim and Milner, 2005; Firestone and Bjeldanes, 2003; Sundar et al., 
2006). Indole-3-carbinol, in the acidic environment of the stomach, dimerizes to form a 
complex mixture of biologically active compounds, identified collectively as acid 
condensation products (Shertzer and Senft, 2000).  The most important one is the dimer, 
3,3'-diindolylmethane (DIM), which is readily detectable in the liver and feces of rodents 
that are fed I3C (Grose and Bjeldanes, 1992) (Figure 6). 
HN NH
3,3'-Diindolylmethane (DIM)
 
Figure 6: The structure of DIM. 
Previous studies on I3C and its dimeric product, DIM, suggest that these 
compounds exhibit the ability to regulate multiple cellular signaling pathways, including 
the PI3K/Akt/mTOR signaling pathway (Rahman and Sarkar, 2005; Wang et al., 2008) 
which is responsible for regulating apoptosis, and therefore may be important in controlling 
cancer. These natural compounds are also active modulators of downstream transcription 
factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling 
which might help explain their ability to inhibit angiogenesis and reverse the epithelial-to-
mesenchymal transition (EMT) phenotype (Ahmad et al., 2013). Since the structure of I3C 
is almost exclusively indole itself, with only the pendant methane chain extra, its biological 
activity is almost certainly related to this important privileged motif. 
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1.2.2.2.2 Sunitinib 
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Figure 7: Structure of sunitinib with the 2- indolinone (indole-like) core highlighted. 
Sunitinib (Sutent™, Pfizer) (Figure 7), previously known as SU11248, is an orally 
available, small-molecule, which targets multiple tyrosine kinases and was approved by the 
United States Food and Drug Administration (USFDA) for the treatment of renal cell 
carcinoma and imatinib-resistant gastrointestinal stromal tumour in 2006 (FDA, 2006). It 
was the first cancer drug simultaneously approved for two different cancers i.e., renal cell 
carcinoma and imatinib-resistant gastrointestinal stromal tumour. The simultaneous 
inhibition of its target kinases leads to decreased tumour vascularisation and cancer cell 
death. A recent study showed that sunitinib could induce apoptosis in glioblastoma 
multiforme (GBM) cells (Joshi et al., 2012), and accordingly it has been studied in more 
than 435 clinical trials for various cancers and its phase II trials for recurrent anaplastic 
astrocytoma and GBM has just been completed (Clinicaltrials.gov, 2013). However, 
importantly, its improved biological activity over the related compound, imatinib, can be 
associated with this indole like structural motif, since such a core is not present in imatinib. 
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1.2.2.2.3 Enzastaurin 
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Figure 8: Structure of enzastaurin with the two indoles highlighted. 
Enzastaurin (LY317615.HCl) (Eli Lilly), (Figure 8) is a novel, synthetic, acyclic 
bisindolylmaleimide anti-angiogenic and anti-neoplastic agent which acts by inhibiting 
protein kinase C (PKC) (Chen and LaCasce, 2008), and a notable feature of its structure is 
that it contains two indoles in its core. Enzymes of the PKC family regulate various cellular 
functions such as cell growth, tumour cell proliferation and apoptosis (Parker, 1999) and it 
has been suggested that PKC-β is the major mediator of vascular endothelial growth factor 
(VEGF)-induced cell proliferation (Takahashi et al., 1999). Moreover, enzastaurin acts as a 
selective inhibitor of PKC-β resulting in the blockade of the VEGF pathway and the 
intracellular Akt signalling (Graff et al., 2005); it has direct anti-cancer activity either alone 
or in combination with other anti-neoplastic agents (Dreicer et al., 2013).  
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1.2.2.2.4 Cediranib 
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Figure 9: Structure of cediranib with the indole core highlighted. 
Cediranib (AZD2171) (RecentinTM, AstraZeneca) (Figure 9) is a potent small 
molecule TKI of VEGFRs, which also targets c-KIT (stem-cell factor) and platelet derived 
growth factor receptor-α (PDGFR-α) (Wedge et al., 2005; Brave et al., 2011) and it is an 
indole-ether quinazoline derivative with potent anti-cancer activities. Research has shown 
promising results in glioma treatments, leading to a 6-month progression-free survival in 
phase II clinical trials (Batchelor et al., 2010). The effectiveness of cediranib has been 
associated with its anti-angiogenic properties and the ability to normalise tumour 
vasculature and alleviate oedema in glioma patients (Kamoun et al., 2009). Regardless of 
the potential this agent holds for the treatment of glioma, the identification of biomarkers 
for response prediction to its therapy is still a major issue that needs to be addressed 
(Martinho et al., 2013), a limitation  that could be solved by developing new compounds 
for the treatment of this disease. 
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1.2.2.2.5 Vinblastine 
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Figure 10: Structure of vinblastine with the two indoles highlighted. 
Vinblastine (Velbe®, Genus Pharmaceuticals) (Figure 10), is a microtubule 
inhibitor of the vinca alkaloid class and is used to treat various kinds of cancers, such as 
non-small cell lung cancer, head and neck cancer, testicular cancer, breast cancer and 
Hodgkin’s lymphoma (Evans, 2009). The vinca alkaloids are just some of the bis-indole 
alkaloids which are known to possess anti-cancer activity by inhibiting mitosis and 
microtubule formation (Evans, 2009). Research has shown that treatment of cells with 
vinblastine causes M-phase specific cell cycle arrest by disrupting microtubule assembly, 
improper formation of the mitotic spindle and the kinetochore (Jordan et al., 1992). Both of 
these factors are essential for the separation of chromosomes during anaphase of mitosis. 
While many microtubule-targeting agents can either inhibit or promote microtubule 
polymerization, vinblastine can accomplish both of these functions. For example, at low 
concentrations (<100 nM), vinblastine inhibits the exchange of tubulin subunits at the plus 
ends of microtubules, effectively stabilizing its dynamics. At medium concentrations (100 
nM – 1 μM), vinblastine promotes depolymerisation of microtubules, while at higher 
concentrations (>1 μM), it causes the formation of tubulin paracrystals (Jordan et al., 
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1992); the result of disrupting the microtubule dynamics is usually apoptosis and cell death, 
therefore such compounds are currently of high interest in the development of new cancer 
treatments.  
1.2.2.2.6 Vincristine 
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Figure 11: Structure of vincristine with the two indoles highlighted. 
Vincristine (Oncovin ®, Genus Pharmaceuticals) (Figure 11), is also a vinca 
alkaloid and is therefore structurally similar to vinblastine. It is formed by the coupling of 
the indole alkaloids vindoline and catharanthine in the vinca plant, and it too causes mitotic 
inhibition which is beneficial for cancer chemotherapy (Evans, 2009). Vincristine binds to 
tubulin dimers, inhibiting the assembly of microtubule structures and arresting mitosis in 
metaphase (Owellen et al., 1972).  
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1.2.2.2.7 1-Benzyl-indole-3-carbinol 
N
OH
 
Figure 12: Structure of 1-benzyl-indole-3-carbinol with the indole core highlighted. 
1-Benzyl-indole3-carbinol (Figure 12) is a new and significantly more potent I3C 
analogue. A recent study reported that 1-benzyl-I3C is the most effective synthetic 
derivative of I3C to date (Aronchik et al., 2012; Nguyen et al., 2010), and in comparison to 
I3C, this novel derivative exhibited circa 1000-fold enhanced potency in suppressing the 
growth of both oestrogen independent (MDA-MB-231) and oestrogen responsive (MCF-7) 
human breast cancer cells (Nguyen et al., 2010).  
1-Benzyl-I3C induces G1 cell cycle arrest at very low concentrations (IC50 of 0.05 
μM) and causes the key I3C-specific effects on the expression and activity of G1 acting cell 
cycle genes, including the disruption of endogenous interactions of the Sp1 transcription 
factor with the CDK6 promoter. It also inhibits the in vivo growth of human breast cancer 
cell-derived tumour xenografts in athymic mice (Nguyen et al., 2010). Since the only 
treatment options currently available for breast cancer are chemotherapy, radiation therapy, 
hormone therapy, immune therapy and/or the surgical removal of the breast, the in vivo and 
cellular anti-proliferative properties of 1-benzyl-I3C and the low effective dose makes this 
novel I3C-derivative a promising drug candidate for its future development as a therapeutic 
agent for human reproductive cancers, and an attractive lead compound for the treatment of 
other cancers too. 
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1.2.2.2.8 SR13668 
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Figure 13: Structure of SR13668 with the two indoles highlighted. 
Indole-3-carbinol, is extremely unstable under physiological conditions and upon 
degradation produces four condensation products, all of which possess anti-cancer activity 
(Rahman and Sarkar, 2005). Based on this, these four products were used as the starting 
point to design a novel class of indole analogue in order to find the most potent protein 
kinase B inhibitor (Akt). SR13668 (Figure 13), the most promising analogue discovered 
(Chao et al., 2007), is a bis-indole with potent in vitro and in vivo activity against various 
cancers and promises to be a cancer chemopreventive agent too (Green et al., 2011). It is a 
serine/threonine Akt inhibitor with potential anti-neoplastic and anti-angiogenic activities 
and it inhibits the activity of Akt, which may result in the inhibition of the PI3K/Akt 
signalling pathway and tumour cell proliferation, leading to cellular apoptosis. It has 
improved in vitro and in vivo stability and activity in comparison to I3C (Chao et al., 2007) 
and is not mutagenic (Doppalapudi et al., 2007).  
Many more indole containing compounds or indole derivatives are being researched 
and tested worldwide for various different types of cancer, and if pursued appropriately, 
this class of compound might open a much needed new avenue for the treatment of glioma. 
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Having such precedent in support of this current study prompted the testing of indoles for 
the treatment of glioma, and if successful, to determine their mechanism of action too. 
1.2.2.3 Indoles as privileged structures 
Privileged structures promise to be an effective approach towards the discovery and 
optimization of novel compounds. Over the past 20 years the privileged structure concept 
has arisen as a productive approach towards the discovery of novel biologically active 
molecules and compounds (DeSimone et al., 2004; Horton et al., 2003). Privileged 
structures are molecular scaffolds with versatile binding properties, such that a single 
scaffold is able to provide potent and selective ligands for numerous biological targets 
through modification i.e. the addition or removal of functional groups. Moreover, 
privileged structures typically show promising drug-like properties such as greater 
absorption, distribution, metabolism, and permeability, which in turn lead to more drug-like 
compound libraries and leads (Horton et al., 2003). The ultimate result is the creation of 
high quality leads that provide a solid base for further development. The crux of the 
identification of ‘privileged’ structures is on highlighting the significance of the structure-
target relationships that confer ‘privileged’ status. This understanding allows ‘privileged’ 
structure based libraries to be targeted at distinct target families (e.g. ROS, autophagy, 
enzymes/kinases). 
The ‘privileged’ nature of the indole-class of compounds suggests that changing the 
substituents at various positions around the indole nucleus will generate new compounds 
with diverse biological activities. In this regard, the 2-arylindole class appears to be one of 
the most promising sub-structures of the indole family which should be researched in more 
depth for their anti-cancer potential. The 2-arylindole sub-structure has shown tremendous 
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biological activity across various biological targets and is present in various anti-tumour 
agents, selective oestrogen receptor modulators (SERM), efflux pump inhibitors and COX-
2 inhibitors (Lal and Snape, 2012). For example, 2-aryl-indolyl maleimides have shown 
potent anti-cancer activity in various in vivo and in vitro models as protein kinase inhibitors 
(Hendricks et al., 1995) whilst the 2-arylindole analogue, 4-(3-phenyl-1H-indol-2-
yl)benzene sulphonamide, is a potent and selective COX-2 inhibitor (Hu et al., 2003). 
INF55 (Figure 14), a substituted 2-arylindole, is a known NorA efflux pump inhibitor in S. 
aureus (Samosorn et al., 2006) whilst, bazedoxifene (Figure 14), a SERM, is one of the 
earliest known examples which shows good receptor binding affinity and mammary tumour 
inhibition in rats (von Angerer et al., 1984). A previous study also showed that 2-aryl-3-
substituted indole derivatives inhibit tubulin polymerisation by binding selectively at the 
colchicine binding site of tubulin and thus inhibiting the cell cycle at the G2/M phase and 
inducing apoptosis (Kaufmann et al., 2007). Moreover, in an in vitro assay against breast 
cancer cell lines, these indole derivatives exhibited comparable potency to combretastatin 
A-4 and vincristine (Kaufmann et al., 2007). 
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Figure 14: Structure of INF55 and bazedoxifene. 
Based on this plethora of indole-based research the indole class of molecules are 
imaginably the most important class of privileged motif in biology. Even within the 
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privileged structural class of the indoles, the 2-arylindoles, just a subset, still demonstrate 
wide-ranging and potent activities. Whether this activity is due to the indole as a whole or 
due to the aromatic moiety at the 2-position, or a combination of the two, remains to be 
seen. Having such a precedent generated strong interest in testing 2-arylindoles as a 
treatment for glioma in this study. 
1.3 Cn-AMP2; a host defence peptide 
In addition to conventional approaches for the development of anti-cancer 
compounds (i.e. small molecules obeying Lipinski’s rules), a number of innovative research 
initiatives have recently been taken to try and identify alternative natural therapies (Harris 
et al., 2013b). One such initiative has involved research on host defence peptides (HDPs), 
which primarily function as innate immune antibiotics but have also been shown to kill 
cancer cells (Hoskin and Ramamoorthy, 2008; Dennison et al., 2006b; Dennison et al., 
2005; Prabhu et al., 2013b). Their anti-cancer activity is facilitated by the fact that, in a 
similar fashion to microbial cells, cancer cells carry an overall negative charge on their 
outer surface, thus allowing their targeting by HDPs, which are generally cationic (Harris et 
al., 2013b; Dennison et al., 2006b). In contrast, around 100 anionic HDPs are known and 
despite their same charge as the cell membrane, it has recently been proposed that, due to a 
unique feature of their cell-death mechanism, these peptides could be investigated for their 
anti-cancer potential (Harris et al., 2013b). In response, the present study has investigated 
the ability of the HDP, Cn-AMP2, from C. nucifera (coconuts), to kill cancer cells (Harris 
et al., 2009b). This peptide was originally isolated from green coconut water, which is the 
clear liquid inside young coconuts and is a popular drink in the tropics, especially in 
Tropical Asia and Latin America. Characterisation of Cn-AMP2 showed that it has a net 
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charge of -1, a molecular weight of 1265 g/mol and that it exhibits broad-spectrum anti-
microbial activity, which was predicted to involve the adoption of α-helical secondary 
structure (Pelegrini et al., 2011; Mandal et al., 2009). As such, it was studied here in order 
to ascertain if it also possesses anti-cancer activity, not least because the molecular weight 
of this peptide fits nicely between small molecules (molecular weight <800 g/mol – see 
section 1.2) and mAbs (molecular weight ~150 kDa, of which bevacizumab belongs and is 
approved for the treatment of various cancers), and thus its study may provide access to 
further lead compounds with which to develop into useful therapies for glioma. 
1.4 Mechanisms involved in cell death 
Having outlined the types of compounds of interest to us, it is important to be able 
to determine the type of cell death occurring and the mechanism of action taking place with 
any active compounds developed. Knowing such information should therefore aid in the 
future development of the compounds identified.  
Cell death can be classified according to its morphological appearance (which may 
be apoptotic, necrotic, autophagic or associated with mitosis), enzymological (with and 
without the involvement of nucleases or of distinct classes of proteases, such as caspases, 
calpains, cathepsins and transglutaminases) and functional aspects (programmed or 
accidental, physiological or pathological) (Melino, 2001). A cell should be considered dead 
when any one of the following molecular or morphological criteria is met: (i) the cell has 
lost the integrity of its plasma membrane, as defined by the incorporation of vital dyes (e.g., 
PI and trypan blue) in vitro; (ii) the cell, including its nucleus, has undergone complete 
fragmentation into discrete bodies (which are frequently referred to as ‘apoptotic bodies’); 
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and/or (iii) its corpse (or its fragments) has been engulfed by an adjacent cell in 
vivo (Kroemer et al., 2009). 
Programmed cell-death (PCD) is the death of a cell in any form mediated by an 
intracellular programme (Engelberg-Kulka et al., 2006), as opposed to necrosis, which is a 
form of traumatic cell-death that results from acute tissue injury and aggravates an 
inflammatory response. Type I and Type II PCD are regularly carried out in a regulated 
process which usually results in an advantage developing during an organism's life cycle. 
There are three main types of programmed cell death known: 
 Apoptosis or Type I programmed cell-death 
 Autophagic or Type II programmed cell-death 
 Necrosis or Type III programmed cell-death 
1.4.1 Apoptosis 
The expression ‘apoptosis’ was coined by Kerr et al. in 1972, and it is one of the 
main types of PCD and comprises a series of biochemical events leading to a characteristic 
cell morphology and death. More precisely, a series of biochemical events that lead to 
various morphological changes, including changes to the cell membrane, such as loss of 
membrane integrity and attachment, cell shrinkage, blebbing, nuclear fragmentation, 
chromosomal DNA fragmentation and chromatin condensation (Keith, 2008). One of the 
main differences in apoptosis and necrosis is the process of cellular debris disposal whose 
result does not cause any harm to the organism. Apoptosis, in general, results in advantages 
during an organism's life cycle as opposed to necrosis which is a form of traumatic cell 
death resulting from acute cellular injury. For example, the fingers and toes in a developing 
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human embryo are differentiated because the cells between the fingers apoptose, resulting 
in separate digits. For an average child between the ages of 8 and 14, approximately 20 to 
30 billion cells die per day while 50 to 70 billion cells die per day due to apoptosis in the 
average human adult. In a year, this accounts for the subsequent destruction and 
proliferation of a mass of cells equal to an individual's body weight (Mukherjee, 2008).  
1.4.2 Autophagy 
Autophagy is a highly conserved process of cellular degradation in eukaryotes by 
which damaged cytoplasmic proteins and organelles are delivered to the lysosome for 
degradation (Klionsky, 2007). It was originally named as a process of protein recycling and 
is termed as Type II PCD. The process is characterised by sequestration of bulk 
cytoplasmic proteins and organelles in autophagic vesicles, and subsequent delivery, to and 
degradation by, the lysosomal system. The process of autophagy is, in-part, characterised 
by the formation of acidic vesicular organelles (AVOs) which can be detected and 
measured by staining with acridine orange (Prabhu et al., 2013a). During autophagy, parts 
of the cytoplasm or organelles are sequestered into double-membrane structures termed 
autophagosomes or autophagic vacuoles (Figure 15) (Klionsky, 2007). Two important 
functions have been suggested for this process. Firstly, autophagy is a short-term stress 
response to a nutrient starved condition or during amino-acid insufficiency; by degrading 
the cell’s own cytoplasmic components into lysosomes, cells get substrates for both vital 
protein synthesis and energy metabolism (Meijer and Codogno, 2004). Secondly, 
autophagy has been proposed to play a role in Type II cell death (Gozuacik and Kimchi, 
2004). Cells treated with chemical agents such as arsenic trioxide (Kanzawa et al., 2003; 
Kanzawa et al., 2005) or cells which overexpress tumour suppressor proteins, such as the 
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short mitochondrial form of p19ARF, induce an autophagic response that causes cell death 
(Reef et al., 2006).  
 
Figure 15: Diagram showing the important steps during autophagy.  
(Available at http://www.mc.uky.edu/biochemistry/labs/wang/interests1.htm) (A) Induction of autophagy 
leads to cytoplasm sequestering into double-membrane structures called autophagosomes, (B) autophagosome 
fuses in the cytoplasm with a lysosome, and (C) lysosome is converted into an autolysosome where the 
contents are degraded. 
 Autophagy has been a topic of great interest for scientists for over 50 years, but has 
been limited due to the lack of knowledge about the molecular machinery behind this 
process (Reggiori and Klionsky, 2002), however, extensive research and genetic screens in 
yeast (S. cerevisiae) have led to the identification of over 30 autophagy-related genes 
(ATG) (Klionsky et al., 2003). Autophagy can be separated into three types viz: macro-
autophagy, micro-autophagy and chaperone-mediated autophagy (CMA), these three types 
vary in their physiological functions and modes of degradation but all have in common the 
degradation of intracellular components via the lysosome (Maria Cuervo, 2004). 
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1.4.3 Necrosis 
Necrosis, in contrast to apoptosis, which is a naturally occurring cause of cellular 
death, has been observed to be a form of accidental cell death brought about by injury to the 
cell by pathogens or toxins (Kroemer et al., 2009). It is caused by factors external to the 
cell or tissue, such as infection or trauma and is a Type III PCD. Necrosis is almost always 
unfavourable and can be fatal, in contrast to apoptosis, which often provides beneficial 
effects to the organism. It is often necessary to remove necrotic tissue surgically by a 
process known as debridement, because cells undergoing necrotic cell death do not usually 
send the same chemical signals to the immune system as cell undergoing apoptosis. This 
prevents nearby phagocytes from finding and engulfing the dead cells, which leads to the 
deposition of cell debris at or near the site of cell death (Kroemer et al., 2009). 
1.5 Hypothesis and aims of the research 
Substituted indoles and related structures are known to exhibit potent anti-cancer 
activity against human breast cancer cell lines (Wang et al., 2006), and various other 
factors, such as their biological activity, the fact that they are privileged structures, and the 
presence of the indole nucleus in various commercial anti-cancer drugs, therefore led to the 
choosing of indoles for the current study. As such, it was decided to investigate if there was 
any anti-cancer activity with indoles against glioma cell lines (1321N1 and U87MG) using 
a number of different cell-based assays and also comparing them with conventional anti-
cancer drugs in vitro.  
Once lead compounds were identified, the aim would be to optimise their structures 
and try to determine preliminary structure-activity-relationships and try to find out how 
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they may be exerting any observed effects. Therefore, various analogues, structurally 
similar to the potent compounds, would be purchased, or prepared, in an attempt to see if 
activity could be affected in any way through structural manipulations. 
Research has shown that, in general, 2-arylindoles are known to be active in a wide 
range of therapeutic areas (Horton et al., 2003; Lal and Snape, 2012) and therefore, the 
structure-activity-relationship screening would be divided into two main categories: indoles 
without the 2-aryl group and indoles with the 2-aryl group. For clarification, aryl refers to 
any functional group or substituent derived from a simple aromatic ring, be it phenyl, 
thienyl, indolyl, etc. The most promising compounds would also be tested on the non-
cancerous SVGp12 cell line to check for compound specificity towards cancer cells. 
In addition, a separate short study was conducted in response to recent studies at 
UCLan (Harris et al., 2013b; Harris et al., 2009b) which suggest that anionic host defence 
peptides (HDPs) may possess anti-cancer potential, and therefore using the assays and 
expertise developed during the work with indoles, the ability of the plant HDP, Cn-AMP2, 
to kill cancer cells, was investigated on glioma cells lines in vitro as well. 
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2. MATERIALS AND METHODS 
2.1 Cell culture 
Commercially available glioma cell lines 1321N1 (astrocytoma grade II) and U87MG 
(astrocytoma grade IV/glioblastoma) were obtained from the European Collection of Cell 
Cultures (ECACC) while SVGp12, a non-cancerous foetal glial cell line was obtained from 
the American type culture collection (ATCC). As this project was focussed on finding 
novel compounds for glioma treatment, the novel compounds used in this study were tested 
on the 1321N1 and U87MG cell lines since both cell lines were derived from malignant 
gliomas. SVGp12 being a non-cancerous cell line was used in certain experiments only, to 
determine the specificity of the compounds towards cancerous cells. 
1321N1 is a human astrocytoma cell line isolated in 1972 as a sub clone of the cell 
line 1181N1 which in turn was isolated from the parent line U-118 MG [one of a number of 
cell lines derived from malignant gliomas by J. Ponten (Ponten and Macintyre, 1968)]. 
U87MG was derived from a malignant glioma from a female patient by explant culture. 
Explant culture is a technique used for the isolation of cells from a piece or pieces of tissue. 
This is also one of a number of cell lines derived from malignant gliomas by J. Ponten and 
associates from 1966 to 1969 (Ponten and Macintyre, 1968). The SVGp12 cell line was 
established by transfecting cultured human foetal glial cells from brain material dissected 
from 8 to 12 week old embryos with DNA from a Simian vacuolating virus 40 (SV40) and 
is a non-cancerous cell line. Both 1321N1 and U87MG cell lines exhibit an epithelial 
morphology (ECACC, UK) while the non-cancerous SVGp12 cell line shows fibroblastic 
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morphology (ATCC, UK). All the above cell lines used in this study were characterised 
within the biomedical research unit (BRU) at UCLan and indicated that the above 
mentioned cell lines were glial and of human origin. 
The 1321NI cell line was maintained in Dulbeccos’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % (v/v) FBS and 2 mM L-glutamine, while the U87MG 
and SVGp12 cell lines were maintained in Essential Minimum Eagle Medium (EMEM) 
supplemented with 10 % (v/v) FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and 1% 
(v/v) non-essential amino acids (NEAA) (Lonza, UK). Short-term glioma cell cultures 
derived from surgical biopsies from patients with WHO grade IV astrocytoma designated 
as IN859 was generously given by Professor Tim Dawson from the Royal Preston Hospital. 
The primary cell line was maintained in Ham’s F-10 medium supplemented with 10% (v/v) 
FBS. All the cell lines were cultured in 75 cm2 tissue culture treated flasks (Thermo 
Scientific Nunc, UK) and maintained in a 37°C humidified incubator supplied with 5% 
CO2. For all the experiments, each of the glioma cell lines were used between passages 2-
20 while the primary cell line was used between passages 3-7. 
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Table 2: Media, reagents, supplements and storage conditions. 
Reagents Abbreviations 
and storage 
temperature 
Formulations Suppliers 
Dulbecco’s 
modified eagle’s 
medium 
DMEM, 2-8 °C 25 mM HEPES, 1.0 g/l glucose, 
1.0 mM sodium bicarbonate, 
0.011g/l phenol red. 
Lonza, 
UK 
Eagle’s minimum 
essential medium 
 
EMEM, 2-8
 
°C 10 mM HEPES, 4.5 g/l glucose, 
2.0 g/l sodium bicarbonate, 
1.0mM sodium pyruvate, 
0.0053 g/l phenol red. 
Lonza, 
UK 
Foetal bovine 
serum, Australian 
origin foetal bovine 
serum (for primary 
cells) 
FBS, -20 °C Heat inactivated FBS. GIBCO, 
UK 
L-glutamine -20 °C 200 mM L- glutamine. Lonza, 
UK 
0.5% Trypsin-
EDTA (10x) 
-20 °C 0.21 mM trypsin, 146 mM  
sodium chloride, 4.8 mM  
EDTA 
Gibco, 
UK 
Non essential amino 
acid 
2-8 °C 100 X non-essential amino acid. Lonza, 
UK 
Phosphate buffer 
saline (PBS, 1x) 
2-8 °C 8 g/l NaCl, 0.2 g/l KCl, 
1.44 g/l Na2HPO4  
0.24 g/l KH2PO4. 
Fisher, 
UK 
Trypan blue (0.4 %) 
 
Room temperature 0.81 % sodium chloride, 0.06 % 
potassium phosphate, dibasic 
Sigma, 
UK 
Dimethyl sulfoxide DMSO, Room 
temperature 
99.5 % dimethyl sulfoxide, 
0.81 % sodium chloride 
Sigma, 
UK 
Ham’s F-10 
medium 
2-8
 
°C 20 mM HEPES, 1.2 g/l sodium 
bicarbonate 
Sigma, 
UK 
Hank’s balanced 
salt solution 
HBSS, 2-8 
 
°C 1 mM calcium chloride, 0.49 
mM magnesium chloride, 0.40 
mM magnesium sulfate, 5.3 
mM potassium chloride, 0.44 
mM potassium phosphate 
monobasic, 4.1 mM sodium 
bicarbonate, 138 mM sodium 
chloride, 0.34 mM sodium 
phosphate dibasic, 5.5 mM D-
glucose 
Gibco, 
UK 
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2.1.1 Thawing cryopreserved cells 
The cryopreserved cells were fragile and required careful handling. These cells were 
thawed as quickly as possible and plated into the fresh growth medium. However, if the 
cells were sensitive to the cryopreservative like DMSO, they were centrifuged before 
plating so as to remove the cryopreservative. In this study, the culture medium was pre-
warmed to 37°C and 10 ml of it was pipetted into the 75 cm2 culture flasks per 1 ml of 
frozen cells. Cryovials were removed from liquid nitrogen and quickly defrosted in a 37°C 
water bath. Once thawed, the vials were sprayed with 70 % ethanol and the contents of the 
vial directly transferred into fresh media contained in a culture flask, in the laminar flow 
hood. After 12-24 h of incubation the medium was replaced with fresh growth medium to 
remove the cryopreservative. 
2.1.2 Subculture 
Once the cells achieved 70-80% monolayer confluency they were sub 
cultured/passaged in a laminar flow hood to maintain sterile conditions and to avoid 
contamination. The respective culture medium for the cell line to be passaged, phosphate 
buffered saline (PBS), and trypsin (all sterile) were all pre-warmed in the 37°C water bath 
for about 30 min to equilibrate the temperature. The medium from the flask to be passaged 
was aspirated and the flask was washed with PBS (5 ml for 75 cm2 and 2 ml for 25 cm2 
flasks) to remove any trace of serum from the cells. The PBS was then removed and 1X 
trypsin was added to the flask (2 ml for 75 cm2and 1ml for 25 cm2 flasks) and incubated at 
37°C for 2-5 min to detach the adherent cells. After 5 min the flask was viewed under the 
inverted light microscope to check for the detachment of cells and was tapped gently to aid 
removal. To this trypsinised flask, 2 ml of the respective culture medium was then added to 
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neutralize the trypsin reaction and prevent any damage to the cell membranes. The medium 
was pipette mixed to break down any large cell clumps and the cell suspension was 
transferred to a 15 ml centrifuge tube (Fisher Scientific, UK). The cell suspension was 
centrifuged at 1000 rpm for 5 min and the supernatant was then carefully aspirated, leaving 
a small amount of medium above the pellet. The pellet was then flicked, resuspended in the 
appropriate volume of respective medium and mixed well to obtain a homogenous and 
evenly distributed cell suspension. Cell viability was determined by staining cells with 
trypan blue (Sigma-Aldrich, UK) and the cell count monitored using a Neubauer 
Haemocytometer. The cells were then re-cultured at a cell density of 5x105 cells/ml in a 75 
cm2 flask containing 10 ml of fresh medium to maintain a working stock. 
2.1.3 Cell Counting 
Once the cells were trypsinised, a volume of 50 µl of cell suspension was pipetted 
into a sterile eppendorf. To this suspension another 50 µl of trypan blue (Sigma Aldrich, 
UK) was added. Trypan blue staining helps in counting the number of dead cells. The live 
cells do not take up the stain while the dead cells are stained blue in colour and this can also 
be used as an assay (section 2.3.3) to detect the anti-cancer activity of potential compounds. 
On the Neubauer Haemocytometer (Figure 16A), a cover slip was attached onto the slide 
over the chambers of the haemocytometer using a small amount of moisture, such as an 
exhaled breath. 
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Figure 16: Diagrammatic representation of a haemocytometer. 
(A) A haemocytometer with its dimensions. (B) A haemocytometer loaded with cell suspension (Images taken 
from http://en.wikipedia.org/wiki/File:Haemocytometer_grid.svg and http://www.gene-
delivery.ox.ac.uk/Protocols/Tissue%20Culture%20Protocols/Counting%20Cells/counting_cells.htm). 
The cell suspension (20 µl) containing 10 µl trypan blue was pipetted out on to the 
haemocytometer and was viewed under an inverted light microscope. The microscope was 
focused on 25 squares of one chamber and the number of cells in these squares were 
counted, this step was then repeated for the other chambers as well (Figure 16B). The 
average number of cells in the centre grid (1mm2) of each chamber was counted and this 
number was multiplied by 2x104 to obtain the number of cells per 1 ml of suspension. This 
number would be then used either for seeding the cells in 96 microtiter well plates, tissue 
culture flasks or for cryopreservation. 
2.1.4 Cell freezing 
The cells were passaged and counted as described earlier. The cell pellet was 
resuspended in 1 ml of cell freezing medium consisting of complete growth medium and  
10 % dimethyl sulfoxide (DMSO) for glioma cell lines (1321N1 and U87MG). The 
cryovial containing this cell suspension was placed in ‘Mr. Frosty’ (Nalgene, UK) freezer 
A B 
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container filled with isopropanol and stored overnight at -80oC. The following day the 
cryovials were transferred into liquid nitrogen. 
2.2 Growth curves 
The generation of a growth curve aided the evaluation of the growth characteristics 
of the cells and ensured suitable tissue culture technique was being developed. This study 
was performed to analyse the growth characteristics of the non-cancerous foetal glial cell 
line SVGp12 and human glioma cell lines 1321N1 and U87MG so that the population 
doubling time, exponential phase and lag phase could be determined. The time at which the 
compounds/drugs should be administered on these cell lines would be determined by the 
data obtained from growth curves.  
To generate the growth curves of the cell lines 1321N1, U87MG and SVGp12 each 
cell line was grown in thirty 25 cm2 flasks at a cell density of 10,000 cells/flask with a total 
volume of 5 ml/flask. The day the cells were seeded was considered as day zero. Every day 
three of these flasks (n=3) were trypsinised and the cell count was determined as described 
earlier until the cells reached 100 % confluency. 
Growth curves of cancer cell lines (1321N1 and U87MG) were also generated using a 
CellTiter-Glo® Luminescent Cell Viability Assay (commonly known as the ATP assay, 
Promega UK Ltd) (section 2.3.2). On day zero, 1000 cells/100 µl were seeded in 10 of the 
opaque white 96-well plates. On day one, one of the 96-well plates was equilibrated for 30 
min at room temperature followed by addition of 100 µl of the CellTiter Glo® Reagent in 
the dark.  The contents in the wells were mixed for 2 min in the plate reader to induce cell 
lysis and the plate was then incubated at room temperature for 10 min to stabilise the 
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luminescent signal. The luminescence was then recorded using the Tecan GENios Pro® 
microplate reader. This was repeated every day until day 10 and on each occasion cells 
from two separate wells were counted (n=2). A standard ATP curve was determined by 
seeding a known number of cells (1000, 2000, 4000, 8000, 16000) in the 96 well plates and 
recording their corresponding luminescence on the consecutive day. This standard curve 
was used to determine the number of cells corresponding to a particular luminescence. 
2.3 Cell proliferation assays 
The cell proliferation assays were used for carrying out the in vitro cytotoxicity tests 
to determine the most potent compounds against the glioma cell lines. Commercial drugs 
cisplatin, temozolomide, carmustine, etoposide and gemcitabine were tested on the 1321N1 
and U87MG glioma cell lines to compare and find the most potent drug which can be 
further used as a positive control in the testing of the novel compounds.  
 The cells were prepared for this assay by trypsinising the cells out from the T75 
flasks and then counting them using the techniques described in section 2.1.3 Once the cells 
were counted, approximately 4000 cells/200µl were seeded in 96-well plates (appendix 2) 
(Sarstedt, Leicester, UK). The cells were allowed to attach overnight, fresh drug was added 
the following day and the well plates were incubated according to suitable time points and 
cell viability was measured using two different cytotoxicity assays. The sensitivity of the 
above mentioned glioma cell lines to various anti-cancer drugs and novel compounds were 
tested using a CellTiter 96® AQueous One Solution Cell Proliferation Assay (commonly 
known as the MTS assay, Promega, UK) and a CellTiter-Glo® Luminescent Cell Viability 
Assay (commonly as known as the ATP assay, Promega, UK).  Each concentration of the 
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drugs was added into four separate wells (n=4) and each experiment was repeated at least 
three times. 
The next part of this study was to analyse the cytotoxicity of the novel compounds 
and compare their activity with cisplatin and resveratrol on the above mentioned glioma 
cell lines. For these studies, the glioma cell lines were treated with the commercial drugs 
and resveratrol for 48 h and each concentration of the drug was added into four separate 
wells (n=4) and each experiment was repeated at least three times. Moreover, the non-
cancerous, SVGp12 cell line was also and only used to determine whether the potent 
compounds found in this study were specific to cancer cells. 
A primary short-term culture, IN859 was also used at the end of the study to support 
the results obtained using established continuous cell lines because it resembles more 
similarity towards in vivo testing in comparison to established cell lines, as these cell lines 
may mutate over time. 
2.3.1 MTS assay 
The MTS assay (Figure 17) was used in this study because it gives a quantitative 
result, as opposed to the trypan blue or propidium iodide (PI) assays which only offer a 
qualitative result. This assay was the primary assay used for performing all cell viability 
studies because it is cheaper and less time consuming than the ATP assay. Nevertheless, the 
ATP assay was used on occasion to validate the MTS assay results. Research laboratories 
extensively use such assays across the world to detect cytotoxicity in various compounds, 
and medical agents and evaluating cell membrane integrity is one of the most common 
ways to measure cell viability and cytotoxic effects. Compounds that have cytotoxic effects 
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often cause cell membrane lysis. Vital dyes, such as trypan blue or PI normally cannot enter 
healthy cells; however, if the cell membrane has been compromised, they freely cross the 
membrane and stain intracellular components (Riss and Moravec, 2004). On the other hand, 
some compounds or medical agents can prove toxic without damaging the cell membrane 
i.e. without causing cell lysis and such cytotoxicity cannot be measured using trypan blue 
or PI. In such cases the MTS or similar assays have to be used. The MTS assay measures 
cell viability using a colorimetric reaction in lieu of membrane lysis. It measures the 
dehydrogenase enzyme activity found in the mitochondria of metabolically active cells 
(McGowan et al., 2011). 
 
 
 
 
 
Figure 17: Diagrammatic representation of the MTS assay (Image available at 
http://spotlite.nih.gov/assay/images/2/26/Terry_Riss_aDream_Slides.pdf). 
Viable cells will reduce the MTS reagent to a coloured formazan product which has 
an absorbance maximum at 490-500 nm in phosphate-buffered saline (Mosmann, 1983). 
The main application of this kit allows an assessment of the viability and proliferation of 
cells in cell culture based assays (Petty et al., 1995). The assay can also be used to 
determine the potential cytotoxicity of novel compounds and toxic materials since those 
agents would inhibit or stimulate cell viability and proliferation. The MTS tetrazolium 
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compound (Owen’s reagent) is bio-reduced by cells into a coloured formazan product that 
is soluble in the tissue culture media (Figure 18). This conversion is thought to be 
accomplished by NADPH or NADH produced by dehydrogenase enzymes in metabolically 
active cells. When the amount of purple formazan generated by cells treated with an agent 
is compared with the quantity of formazan produced by untreated vehicle control cells, the 
efficiency of the test agent in causing death, or changing the metabolism of cells, can be 
deduced through the production of a dose-response curve (Wilson, 2000). 
 
Figure 18: Structures of MTS tetrazolium [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] and its formazan product (Adapted from Promega). 
Assay protocol: 
The 1321N1, U87MG and SVGp12 cell lines were trypsinised and cultured 
overnight at a cell density of 3500 cells/200 µl/well, 4000 cells/200 µl/well and 5000 
cells/200 µl/well respectively in 96-well microtitre plates (appendix 2) (Sarstedt, UK). The 
following day when the cells appeared 50-60 % confluent, each concentration of the 
commercial drugs and novel compounds to be studied were added in quadruplicates and left 
for incubation for 48 h. After 48 h, 20 µl of the pre-warmed MTS reagent (Promega, UK) 
was added to each of the wells and the 96-well plates were incubated at 37°C for 60 min. At 
the end of the 60 min period, the absorbance was recorded at 490 nm using the Tecan 
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GENios Pro® microplate reader. The absorbance is directly proportional to the number of 
live cells. Thus, the percentage of cell survival can then be determined using the following 
equation: 
Cell survival (%) =            Absorbance of treated cells x 100                 
                               Absorbance of vehicle control group (untreated cells + solvent) 
2.3.2 ATP assay 
The ATP assay was only used in this study to further validate the results generated by 
the MTS assay. Unlike the MTS assay, the ATP assay can measure cells as low as 4 cells 
per well, in contrast to the MTS assay which can only detect samples containing more than 
1000 cells per wells, as such this makes the ATP assay highly sensitive (Petty et al., 1995), 
and thus a good assay for the corroboration of the MTS assay results, thus proving any 
activity seen is real and repeatable. 
 
 
 
 
 
 
 
Figure 19: Diagrammatic representation of  the ATP assay (assay (Image available at 
http://spotlite.nih.gov/assay/images/2/26/Terry_Riss_aDream_Slides.pdf). 
The ATP assay is a homogeneous method for determining the number of viable cells 
in culture based on the quantitation of the ATP present, a process which signals the 
presence of metabolically active cells (Kangas et al., 1984). The homogeneous “add-mix-
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measure” format results in cell lysis and generation of a luminescent signal proportional to 
the amount of ATP present (Figure 19). The amount of ATP present is directly proportional 
to the number of live cells present in the culture. The ATP assay relies on the properties of 
a proprietary thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), which 
generates a stable long lived glow-type luminescent signal with a half-life of more than five 
hours. Using firefly (P. pyralis) luciferase this luminescence assay is an alternative to 
colorimetric, fluorometric and radio-isotopic assays for the quantitative assessment of 
cytotoxicity and proliferation of cultured mammalian cells (Crouch et al., 1993). 
ATP monitoring can be used to measure the cytocidal, cytostatic and proliferative 
effects of various biological response modifiers, drugs and biological compounds. ATP is 
an indicator for cell viability because it exists in all metabolically active cells and the 
concentration declines significantly when the cells undergo apoptosis or necrosis (Cree and 
Andreotti, 1997). The assay is based on the production of light caused by the reaction of 
ATP with added luciferase and D-luciferin (Figure 20).  
 
 
 
Figure 20: Mono-oxygenation of luciferin is catalysed by luciferase in the presence of Mg2+, ATP and 
molecular oxygen (Adapted from Promega). 
 
Assay protocol: 
The 1321N1 and the U87MG cells were trypsinised and cultured overnight at a cell 
density of 3500 cells/200 µl/well and 4000 cells/200 µl/well respectively in 96-well 
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microtitre plates (appendix 2) (Sarstedt, UK). The following day when the cells appeared 
50-60 % confluent each concentration of the novel compounds mentioned above were 
added in quadruplicates and left to incubate for 48 h. After 48 h, the media was removed 
and replaced with warm PBS and the 96-well plates were equilibrated for 30 min at room 
temperature followed by the addition of 100 µl of ATP Reagent in the dark.  The contents 
in the wells were mixed for 2 min using the Tecan GENios Pro® microplate reader to 
induce cell lysis and the plates were then incubated at room temperature for 10 min to 
stabilise the luminescent signal. The luminescence was then recorded using the Tecan 
GENios Pro® microplate reader. The luminescence obtained is directly proportional to the 
number of live cells. Thus, the percentage of cell survival was then determined using the 
following equation: 
Cell survival (%) =            Luminescence of treated cells x 100                 
                               Luminescence of vehicle control group (untreated cells + solvent) 
2.3.3 Trypan blue dye exclusion test 
The trypan blue dye exclusion test was used in this study to check the time required 
for membrane lysis (cell death) to occur after treatment with certain compounds as this 
cannot be detected by the MTS or the ATP assay. The trypan blue dye exclusion test is used 
for determining the amount of living cells present in a cell suspension and is based on the 
principle that live cells possess intact cell membranes that exclude certain dyes such as 
trypan blue, PI or eosin, whereas dead cells become stained. In this test, the cell suspension 
is mixed with the trypan blue dye in a 1:1 ratio and then visually observed under the 
microscope to determine whether cells take up or exclude the dye. A viable cell will have a 
clear cytoplasm whereas a dead cell will have a blue stained cytoplasm. 
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Assay protocol: 
Cells were trypsinised and 4000 cells/200 µl/well were seeded in 96 well plates 
(appendix 2) (BD Biosciences, UK) and were allowed to attach overnight. Cells were 
treated with 1000 µM and 750 µM of the test compound for various time points (15 min, 45 
min, 75 min, 90 min, 120 min). After the desired treatment time, a volume of around 10 µl 
of trypan blue dye (Sigma Aldrich, UK) was added into the well plate and the cells were 
observed under the microscope for potential trypan blue staining. 
2.4 Preparation of stock solutions of commercial anti-
cancer agents and novel compounds  
The anti-cancer commercial drugs used in this study were cisplatin, carmustine, 
temozolomide, etoposide and gemcitabine. Stock solutions of each drug were prepared as 
mentioned in table 3 and were stored in the freezer at -20°C until required. Either ethanol or 
dimethyl sulfoxide (DMSO) was used to dissolve the various commercial drugs and novel 
compounds. The drugs and compounds were then subsequently dissolved in the culture 
medium of the respective cell line; the final concentration of ethanol or DMSO used was no 
more than 0.5 %. The untreated vehicle controls also contained 0.5 % absolute ethanol or 
DMSO. These concentrations of ethanol and DMSO have no toxic effects on the cell lines 
(Kiyozuka et al., 2001).  
 
 
Chapter II. Materials and Methods 
 
 
 
53 
N
H
193
N
H
147 (I3C)
OH
N
H
208
H2N
N
H
221
O
N
H
Me
161
MeO
N
H
189
O
O
Me
OOH
NO2
257
OO
271
NO2
OOH
NO2
287MeO
OOH
NO2
302
NO2
OOH
NO2
329
CO2Me
OOH
NO2
350
Br
Preliminary intermediates
N
H
223
MeO
N
H
250
AcHN
N
H
223a
OH
N
H
209
HO
Indoles  
Figure 21: Compounds used in the present study. 
All the compounds in Figure 21 were either synthesised or purchased and were labelled 
according to their molecular weights for simplicity and all of these compounds were at least 
95 % pure, as determined by 1H and 13C NMR, and HPLC; as an example of the purity of 
the prepared test compounds, the 1H NMRs for 209 and 223a (Figure 22) are shown below, 
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whilst those compounds that were commercially available (Sigma-Aldrich, UK) were used 
as purchased. For example, indole-3-carbinol (147) and the negative control, 2-
phenylindole (193), were both at least 95 % pure, whilst all other commercially available 
test compounds were also at least 95 % pure, as determined by gas chromatography.  
 
Compound 209 
 
 
 
 
 
 
 
 
Compound 223a 
Figure 22: Selected 1H NMRs of compounds 209 and 223a showing their level of purity. 
For the synthetic protocols and characterisation of the indoles prepared by the Snape 
group and tested herein, see Appendix I. 
H2O CDCl3 
DMSO-d6 
H2O 
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2.4.1 Physiochemical properties of novel indoles 
An octanol-water partition coefficient (Log P) is the ratio of the concentrations of a 
compound in two phases of a mixture of two immiscible liquids at equilibrium (Leo et al., 
1971). Generally, one of the solvents chosen is water, whereas the second 
is hydrophobic such as octanol (Sangster, 1997). Therefore, the partition coefficient is a 
measure of how hydrophilic or hydrophobic a compound is. One rule of Lipinski's “Rule of 
Five” (section 1.2) states that, an orally active drug’s Log P should not be greater than five 
if the compound is to freely distribute around the body and traverse cell membranes; with 
that in mind, table 3 shows the Log P values for the indoles used herein, where it can be 
seen that all values are < 5, as required.  
The indoles used in the current study were found to be lipophilic (table 3) and 
therefore were only soluble in the cell culture media with the concomitant use of an organic 
solvent [ethanol or DMSO]. Whilst this lipophilicity may be problematic for the 
determination of biological activity, it may be beneficial for in vivo activity, since the 
compounds are more likely to be able cross cell membranes and act upon their intracellular 
target(s). 
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Table 3: Log P values (calculated using ChemBioDraw Ultra 11.0) of some of the indoles tested.   
Entry Compounds Log P 
1       209 2.92 
2      223a 2.73 
3       223 3.18 
4       193 3.31 
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Table 4: Drug/compound preparation: Stock solutions were made prior to use. 
Drugs/compounds 
(Supplier) 
Solvent used 
Stock 
concentration 
(mM) 
Final concentrations used 
(µM) 
Cisplatin (Sigma-
Aldrich,UK) 
Culture media 1 10, 20, 50, 100, 300, 500 
Carmustine (Sigma-
Aldrich,UK) 
Dissolved in ethanol, 
subsequently in culture 
media 
1 50, 100, 300, 500 
Temozolomide 
(Sigma-Aldrich,UK) 
Culture media 1 50, 100, 300, 500 
Etoposide (Sigma-
Aldrich,UK) 
Dissolved in ethanol, 
subsequently in culture 
media 
1 50, 100, 300, 500 
Gemcitabine 
(Sigma-Aldrich,UK) 
Dissolved in ethanol, 
subsequently in culture 
media 
1 50, 100, 300, 500 
Novel compounds: 
209, 287, 221,  223, 
223a, 250, 147 (I3C) 
(Sigma-Aldrich,UK) 
Dissolved in ethanol, 
subsequently in culture 
media 
2 1000, 750, 400, 200, 100 
Novel compounds: 
302, 350, 271, 329, 
257, 208, 189, 161, 
193, Resveratrol 
Dissolved in DMSO, 
subsequently in culture 
media 
2 1000, 750, 400, 200, 100 
Ascorbic acid 
(Sigma-Aldrich,UK) 
Culture media 1 500  
3-Methyladenine 
(Sigma-Aldrich,UK) 
Culture media 5 5000 
Acridine orange 
(Sigma-Aldrich,UK) 
Ethanol 0.1  3  
Carboxy-H2DCFDA 
(Invitrogen LTD, 
UK) 
DMSO 10 25 
TBHP (Invitrogen 
LTD, UK) 
HBSS 100 100 
Cn-AMP2 (Pepsyn, 
UK) 
DMSO 4 2000, 1000, 500 
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2.5 Image-iT™ LIVE Green Reactive Oxygen Species 
Detection Kit 
The Image-iT™ LIVE Green Reactive Oxygen Species (ROS) Detection Kit 
(Invitrogen Ltd, UK) was used in this study to validate the hypothesis that certain 
compounds may cause ROS production in the cells leading to oxidative stress. This kit 
provides the key reagents necessary for the detection of ROS in live cells. In addition to 
carboxy-H2DCFDA, the kit provides the common inducer of ROS production, tert-butyl 
hydroperoxide (TBHP), as a positive control. Using this ROS detection kit, oxidatively 
stressed and nonstressed cells are reliably distinguished by fluorescence microscopy. The 
generation of ROS is inevitable for aerobic organisms, and, in healthy cells, occurs at a 
controlled rate. Under conditions of oxidative stress, ROS production is dramatically 
increased, resulting in subsequent alteration of membrane lipids, proteins, and nucleic 
acids. 
 
 
 
Figure 23: Detection of ROS generation by Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit. 
The carboxy-H2DCFDA permeates live cells (Figure 23A). It is deacetylated in the 
live cell by nonspecific intracellular esterases and is converted to carboxy-DCFH (Figure 
23 B). In the presence of nonspecific ROS (produced throughout the cell, particularly 
A B C 
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during oxidative stress) the reduced fluorescein compound, carboxy-DCF (Figure 23C) is 
oxidised and emits bright green fluorescence which can be detected using a confocal 
microscope or a flow cytometer. 
2.5.1 Confocal microscopy 
The above mentioned Image-iT ™ LIVE Green ROS Detection Kit was used to 
detect the reactive oxygen species in the glioma cell lines. The assay was based on carboxy-
H2DCFDA, a reliable fluorogenic marker for ROS in live cells which would fluoresce 
green on the detection of ROS in live cells (Figure 23). A confocal microscope was used to 
visualise the amount of fluorescence produced. As a test run, to make sure that the assay 
worked, it was initially performed using a confocal microscope. Once confirmed it was 
working as expected, all future experiments were performed on a flow cytometer so that the 
amount of fluorescence produced could be quantified.  
Assay protocol: 
Glioma cell lines were trypsinised and 2 x 104 cells of each cell line were seeded in 
6-well plate/ml/well (appendix 2) (BD Biosciences, UK) and the cells were allowed to 
attach overnight. On the day of experiment, cells were treated with  500 µM of the test 
compound and the positive control [tert-butyl hydroperoxide (TBHP) (100 µM)] for 1 h 
followed by labelling with a sufficient amount of 25 µM carboxy-H2DCFDA dye and 
incubated for 30 min at 37°C, protected from light. Cells were gently washed with Hankʼs 
balanced salt solution (HBSS) warm buffer three times and were imaged immediately on 
the Zeiss LSM510 laser confocal microscope at an excitation/emission of 495/529 nm. 
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2.5.2 Flow cytometry analysis 
Flow cytometry is a powerful technology for the simultaneous measurement and 
analysis of multiple parameters of individual cells within heterogeneous populations. It has 
an array of applications ranging from subset identification of heterogeneous cell 
populations, fluorescence-activated cell sorting (FACS) to rare-event detection in stem cell 
analysis. In order to quantify the amount of ROS produced in the glioma cell lines, Image-
iT ™ LIVE Green ROS Detection Kit was again used. 
Assay protocol: 
 Glioma cell lines were trypsinised and 2 x 104 cells/ml/well of each cell line were 
seeded in 6-well plates (appendix 2) (BD Biosciences, UK) and were allowed to attach 
overnight. On the day of the experiment, cells were treated with 500 µM of the test 
compound and the positive control [tert-butyl hydroperoxide (TBHP) (100 µM)] for 1 h 
followed by labelling with sufficient amount of 25 µM carboxy-H2DCFDA dye and 
incubation for 30 min at 37°C, protected from light. The ascorbic acid study followed the 
same protocol with the exception being that cells were co-treated with the test compound 
(500 µM) and ascorbic acid (500 µM) for 1 h. Cells were gently washed with HBSS warm 
buffer three times and then trypsinised, centrifuged and resuspended in 300 µl PBS. Cells 
were filtered through cell strainer caps (35µm mesh) (BD Biosciences) to obtain a single 
cell suspension and analysed using a FACSAria flow cytometer using FITC fluorochrome 
at an excitation/emission of 488/519 nm (BD Biosciences).   
2.5.3 Acridine orange staining 
Acridine orange staining was used in this study to validate the hypothesis that the 
quick cell death caused by one of the test compounds may be due to autophagy, mediated 
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by ROS (oxidative stress).  Acridine orange (AO) is a nucleic-acid selective fluorescent 
cationic dye useful for cell cycle determination (Darzynkiewicz, 1990), and it is commonly 
used to study autophagy since it accumulates in acidic organelles in a pH-dependent 
manner (Han and Burgess, 2010). Acridine orange, due to its metachromatic properties, is 
widely used in fluorescence microscopy and flow cytometry analysis (Darzynkiewicz, 
1991). At neutral pH, AO is a hydrophobic green fluorescent molecule but during 
autophagy, AO becomes protonated and trapped within the acidic vesicles of the organelle 
and emits orange light. It is cell-permeable, and interacts with DNA and RNA by 
intercalation or electrostatic attractions respectively. When bound to DNA, it has an 
excitation maximum at 502 nm and an emission maximum at 525 nm (green). On binding 
with RNA, the excitation maximum shifts to 460 nm (blue) and the emission maximum 
shifts to 650 nm (red) (Darzynkiewicz and Juan, 1997). Acridine orange enters acidic 
compartments such as lysosomes and gets protonated and sequestered. Cells illuminated 
with blue (488 nm) excitation light were measured with flow cytometry. In these low pH 
conditions (during AVO formation), the dye will emit orange light when excited by blue 
light. Thus, AO can be used to isolate engulfed cells, because it will fluoresce upon 
engulfment (Darzynkiewicz and Juan, 1997).  
Assay protocol: 
Glioma cell lines were trypsinised and 2 x 104 cells/ml/well were seeded in 6-well 
plates (appendix 2) (BD Biosciences, UK) and were allowed to attach overnight. After 24 h 
of incubation, the cells were treated with 500 µM of the test compound or the test 
compound (500 µM) + 3-methyladenine (5 mM) for 1 h. After 1 h incubation with the 
compound the cells were stained with 3 µM acridine orange (Sigma, UK) and incubated for 
15 min at 37°C, protected from light. Cells were gently washed with PBS, trypsinised, 
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centrifuged and were re-suspended in 300 µl PBS. Cells were filtered through cell strainer 
caps (35 µm mesh) to obtain a single cell suspension and analysed using a FACSAria flow 
cytometer using a PE-Texas Red fluorochrome at an excitation/emission of 488/615 nm  
(BD Biosciences).  
2.6 Graphical analysis and stock solution preparation of 
the host defence peptide (HDP), Cn-AMP2  
The sequence of the HDP, Cn-AMP2 [TESYFVFSVGM, Thr-Glu-Ser-Tyr-Phe-
Val-Phe-Ser-Val-Gly-Met (where, Thr- threonine, Glu- glutamic acid, Ser- serine, Tyr- 
tyrosine, Phe- phenylalanine, Val- valine, Gly- glycine, Met- methionine)], was obtained 
from Mandal et al, (2009) and that of temporin 1-Ja (ILPLVGNLLNDLL), an amphibian 
host defence peptide, was obtained from Isaacson et al. (2002). The latter peptide was 
chosen as a reference HDP based on its structural similarities to Cn-AMP2, namely, its 
similarity in length and net charge, and its ability to form a well-defined α-helix.  The 
sequence of each of these peptides was then represented as an α-helical wheel, which is a 
two-dimensional axial projection assuming an angular periodicity of 100o (Schiffer and 
Edmundson, 1967), using the software, AntheProt v 5.0 (VanOrder and Lindwall, 1942; 
Deleage et al., 2001). Cn-AMP2 was supplied by Pepsyn (Liverpool, UK), produced by 
solid phase synthesis and purified by HPLC to greater than 95 %, which was confirmed by 
Pepsyn, UK. The peptide was stored as a stock solution of 4 mM in DMSO at -20 °C. The 
peptide was tested for anti-cancer activity on the 1321N1 and U87MG glioma cell lines in 
96-well plates (Sarstedt, Leicester, UK) using the technique described in section 2.3.1 Cn-
AMP2 (final concentrations of 2 mM and 1 mM) was incubated with the 1321N1 and 
U87MG cell lines, which had been cultured in Dulbeccos’s Modified Eagle’s Medium 
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(DMEM), prepared as described in section 2.1, except that the FBS concentration of the 
medium was varied [10 % and 2.5 % (v/v)]. The percent viability of the cells was then 
determined according to the MTS cell viability assay, as described in section 2.3.1, except 
that an incubation period of 72 h was employed. The effect of Cn-AMP2 on the 
morphology of these cells was examined by recording images using an inverted 
microscope. The ability of Cn-AMP2 to lyse membranes of the 1321N1 and U87MG cell 
lines was assayed as described in section 2.3.3 except that: cells were grown in DMEM 
containing 2.5 % (v/v) FBS, and incubated with the peptide at levels of 1 mM and 2 mM 
for 72 h. As controls, these experiments were repeated in the absence of the peptide and, in 
all cases, experiments were performed in quadruplicate. The untreated vehicle controls 
contained 0.5 % DMSO. 
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2.7 Statistical and Data analyses 
Data obtained from these experiments were subjected to statistical analyses using 
GraphPad Prism software (version 6.0, USA) to analyse and compare the control and test 
values. The flow cytometry results were analysed on the BDS FACS DIVA software. All 
data are expressed as mean ±standard deviation (SD). The Log P value of the novel 
compounds was calculated using ChemBioDraw Ultra (version 11.0, PerkinElmer 
Informatics). The data was considered as significant when p < 0.05.  
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3.RESULTS AND DISCUSSION 
Section A: Determination of anti-cancer activity 
using cell viability assays 
3.1 Establishing the growth curves for the glioma cell 
lines. 
To analyse the growth characteristics of the human glioma cell lines 1321N1, 
U87MG and the non-cancerous foetal glial cell line, SVGp12, their growth curves were 
established. This study was performed to determine the population doubling time, 
exponential and lag phases and also to verify and compare the growth patterns obtained 
from the literature to ensure suitable tissue culture technique was being developed. Growth 
curves were plotted using two methods; the flask method and the plate method. In the flask 
method, the cell count was acquired using Neubauer’s Haemocytometer method (Strober, 
2001) and it was observed that the rate of proliferation for the 1321N1 cells was faster than 
the U87MG cell line and both of the cancer cell lines were faster than the non-cancerous 
SVGp12 cell line (Figure 24). The population doubling time for 1321N1, U87MG and 
SVGp12 cell lines was 22 ±2 h, 25 ±3 h and 30 ±2 h respectively. Values which are 
consistent with both the cell types and other studies (Kim et al., 2012; Ke et al., 2000). In 
the plate method (figures 25C and 25D), only the growth curves of the cancerous cell lines 
(1321N1 and U87MG) were determined, and this was performed using the CellTiter-Glo® 
Luminescent Cell Viability Assay. The cell count was acquired by plotting a standard curve 
of cell count against luminescence and comparing the absorbance value obtained with the 
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value obtained in the standard curve. The cell count was acquired using the equation of the 
straight line since the growth is linear (R2~1), as demonstrated on the standard curve 
(figures 25A and 25B). Similar to the flask method, it was observed that the 1321N1 cells 
proliferate at a faster rate than U87MG. The exponential phase observed by the flask 
method for the 1321N1 cell line was from the 3rd to 6th day while for the U87MG was from 
the 4th to 9th day. The exponential phase observed by the flask method for the non-
cancerous foetal glial cell line, SVGp12 cell line was from the 5th to 8th day. The 
exponential phase observed by the plate method for the 1321N1 cell line was from 4th to 6th 
day while for the U87MG was from the 4th to 7th day. Previous studies have shown that the 
doubling time for the 1321N1 cell line to be 22 h (Kim et al., 2012) while that of the 
U87MG cell line to be 29 h (Ke et al., 2000), results which were similar to the those 
obtained from the current study and thus confirmed that the results were consistent with the 
growth patterns shown in the literature for the above mentioned glioma cell lines. 
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Figure 24: Growth analysis of the non-cancerous foetal glial cell line, SVGp12, and the human glioma cell 
lines 1321N1 and U87MG by Neubauer’s Haemocytometer method.  
Note that the exponential phase is reached on the 3rd day for the 1321N1, 4th day for the U87MG and on the 
5th day for the SVGp12 cell lines while the plateau phase is reached from the 6th day for the 1321N1 cell line 
and 9th day for the U87MG cell line. The data points are means of three repeats and the error bars represent ± 
standard deviation (±SD). 
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Figure 25: Growth analysis of glioma cell lines 1321N1 and U87MG using the ATP assay where the R2 value 
is the correlation coefficient.  
A) Standard curve for the 1321N1 cell line. B) Standard curve for the U87MG cell line. C) Growth curve for 
the 1321N1 cell line where the exponential phase is from the 4th-6th day. D) Growth curve for the U87MG cell 
line where the exponential phase is from the 4th-7th day. The data points are means of 2 repeats. 
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Typical cell growth shows three phases, viz; a lag phase, which denotes the time 
taken by the cells to recover from subculture, attach to the surface of the flask or well and 
spread; the log phase which represents the phase in which the cell numbers begin to 
proliferate exponentially, and a second lag phase in which the cell culture becomes 
confluent and the growth rate slows down or stops and the curve looks like a plateau when 
plotted on a graph. It was observed by both the methods used, that the rate of proliferation 
in the exponential phase for the 1321N1 cell line was faster than the U87MG (section 3.1). 
The doubling time of the SVGp12 cell line was the slowest throughout, making it the most 
slow growing cell line compared to the two cancerous cell lines tested; it is clear therefore 
that cancer cells multiply faster than the non-cancerous ones, as expected and shown in the 
literature (Cooper, 2000). 
3.2 Cell proliferation and viability measurements of 
glioma cell lines in the presence of the test 
compounds. 
3.2.1 Determining the best commercial compound to be used as a 
positive control in vitro 
The commercial drugs cisplatin, carmustine, etoposide, gemcitabine and 
temozolomide were used in this study and tested on both the 1321N1 (Figure 26) and 
U87MG (Figure 27) cell lines in order to find the most potent drug which can be further 
used as a positive control in the testing of these compounds. This would also enable to 
allow a comparison to be made between these established anti-cancer drugs and the 
compounds tested later. The concentrations used were 10 µM, 20 µM, 50 µM, 100 µM, 300 
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µM and 500 µM. The IC50 value was reached at a concentration of 11 ±2 µM after treating 
with cisplatin and 50 ±2 µM for gemcitabine after 48 h on the 1321N1 cell line. However, 
the more malignant U87MG cell line was resistant to all the above commercial drugs, 
except for cisplatin, where the IC50 value was reached at a concentration of 310 ±4 µM after 
treatment for 48 h. The following dose response curves were plotted using the MTS cell 
proliferation assay. 
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Figure 26: Dose response curves of cisplatin, carmustine, etoposide, gemcitabine and temozolomide on the 
1321N1 cell line after treatment for 48 h. The data points are means of 4 repeats and the error bars represent 
±SD. 
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Figure 27: Dose response curves of cisplatin, carmustine, etoposide, gemcitabine and temozolomide on the 
U87MG cell line after treatment for 48 h. The data points are means of 4 repeats and the error bars represent 
±SD.  
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3.2.1.1 Cisplatin as a positive control 
The results of the cytotoxic analysis showed that cisplatin was the most potent of all 
commercial drugs (etoposide, carmustine, temozolomide and gemcitabine) tested (Figure 
26 and Figure 27) and therefore it was used from here on as a standard comparison against 
all other test compounds. These cytotoxicity results showed that the IC50 values were 
reached on both of the glioma cell lines (1321N1 and U87MG) within 48 h of treatment 
with cisplatin. These results are consistent with previous studies which have shown that 
both these glioma cell lines are sensitive to cisplatin and cell death is induced through 
apoptosis (Raaphorst et al., 1998; Shervington et al., 2009). 
Cisplatin possesses its anti-cancer activity because of its interaction with 
chromosomal DNA after it enters into the cell via either active or passive diffusion 
(Kazanietz, 2010). Over the years cisplatin has shown significant impact on the treatment 
of multiple neoplasms and was also one of the key reasons behind selecting this drug herein 
as a comparison against the test compounds on the glioma cell lines (Helm and States, 
2009; Matsuzaki et al., 2000). For example, research has shown that cisplatin is also a Fas 
inducer which makes oesophageal tumours susceptible to the Fas antigen, a feature which 
results in apoptosis (Matsuzaki et al., 2000); the Fas receptor is a death receptor on the 
surface of cells that leads to apoptosis, and these studies have shown that the anti-cancer 
effect of an anti-Fas antibody on the oesophageal cancer cell line was enhanced by pre-
treatment with cisplatin. DNA fragmentation was observed in a cell line that was treated 
with both cisplatin and this anti-Fas antibody and it ultimately led to cell apoptosis, whilst 
an anti-Fas neutralising antibody inhibited this cytotoxicity (Matsuzaki et al., 2000). 
Therefore, comparing the results of the test compounds developed herein with cisplatin, 
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using the same cell lines, will enable the potential of the compounds, as leads, to be 
determined. 
3.2.2 Preliminary test compounds in comparison with cisplatin and 
resveratrol 
The interest in indoles, and in particular 2-arylindoles, by the Snape research group 
(Snape, 2008; Lal and Snape, 2012) has resulted in a number of pure synthetic 
intermediates being available which share structural similarities to the 2-arylindoles for 
which they are precursors, as such, the initial study began by testing a few of these 
intermediates (Snape, 2008) in the hope of a) discovering novel anti-cancer activity and b) 
providing basal activity which could potentially be improved upon if the compounds were 
converted to their indole counterparts. Moreover, in support of this study, these 
intermediates share structural similarities with resveratrol, a known anti-cancer agent which 
has been the subject of a vast amount of research over the past 15 years (Jo Atten et al., 
1998; Jiang et al., 2005; Li et al., 2009; Gagliano et al., 2010; Wcislo, 2014; Liu et al., 
2014). 
Dose response curves of cisplatin, resveratrol and the various novel intermediates 
(Figure 28 and Figure 29) on the 1321N1 and U87MG cell lines were plotted using the 
MTS cell proliferation assay, wherein both these cell lines were exposed to different 
concentrations of the compounds for 48 h, in order to assess this cytotoxicity; cisplatin and 
resveratrol were used as positive controls. As mentioned above, these intermediates were 
compared to cisplatin, since it was found to be the most potent compound on both the 
glioma cell lines of interest (section 3.2.1), amongst all other commercial drugs tested, and 
also with resveratrol, because the test compounds share structural similarities with 
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resveratrol, a known anti-cancer agent (Gagliano et al., 2010). As shown in Figure 28 and 
Figure 29, the IC50 value of cisplatin was 11 ±2 µM on the 1321N1 cell line and 310 ±4 µM 
on the U87MG cell line, whilst, resveratrol showed moderate activity on the 1321N1 cell 
line but proved inactive on the U87MG cell line. For the structures of the intermediates 
tested, see Figure 21, section 2.4. 
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Figure 28: Various novel compounds tested in comparison with cisplatin and resveratrol for 48 h on the 
1321N1 cell line. The data points are means of 4 repeats and the error bars represent ±SD.  
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Figure 29: Various novel compounds tested in comparison with cisplatin and resveratrol for 48 h on the 
U87MG cell line. The data points are means of 4 repeats and the error bars represent ±SD.  
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Without exception, all of the above test compounds failed to show any significant 
activity compared to either cisplatin or resveratrol, on both the glioma cell lines studied. 
Within the experimental variation obtained by the error bars, none of the compounds, 
against either cell line, managed to reduce the cell viability below 80 %.  Unlike cisplatin, 
which saw a rapid fall to approximately 30 % and 50 % cell viability, in 1321N1 and 
U87MG respectively, at relatively low concentrations.  
Despite this, a previous study in A549 lung cancer cells showed that resveratrol acts 
by up-regulating p53 and p21 proteins and induces apoptosis by the activation of caspases 
by disrupting the mitochondrial membrane complex after exposing the cells for 48 h with 
resveratrol (Whyte et al., 2007). Thus, the results from the current study in accordance with 
the above mentioned literature indicate that resveratrol behaves differently with different 
cell types even when the exposure time is kept constant, as evidenced by the activity of 
resveratrol observed on the 1321N1 and A549 cell lines but none on the U87MG cell line. 
These results suggest that although the test compounds are phenolic and structurally 
similar to the known anti-cancer agent resveratrol, there must be some other particular 
structural feature of resveratrol which is responsible for its activity against the 1321N1 
cancer cell line, a feature which is not present in the above tested intermediates. 
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3.2.3 Privileged indoles in comparison with cisplatin and resveratrol 
Since the test compounds in Figure 28 and Figure 29 did not show any significant 
activity, six indoles were purchased including compounds 193 and 147 (I3C). Compounds 
147 (I3C) and 193 were chosen since it has been shown that both have established activity 
against cancer cells (Lal and Snape, 2012), moreover, compound 193 is also a 2-arylindole, 
compounds which are known to be biologically potent (section 1.2.2.3). Compounds 208 
and 221 are also readily available 2-arylindoles with further structural modifications which 
may be useful for producing structure-activity-relationships, whilst compounds 161 and 
189 are indoles which lack the 2-aryl group for comparison (Figure 30). As discussed 
previously, resveratrol (a naturally occurring phytoalexin that is present in grapes, red wine, 
berries and peanuts and has been studied extensively for its anti-cancer properties 
(Gagliano et al., 2010; Li et al., 2009; Jiang et al., 2005)) was also used here as a 
comparison since it is structurally similar to the 2-arylindoles and is also a known natural 
anti-cancer agent (Gagliano et al., 2010). As Figure 30 (box) shows the aromatic rings and 
linking carbons of compound 193 and resveratrol overlap well, although the hydroxyl 
groups of resveratrol are superfluous. Nevertheless, the importance of these hydroxyl 
groups’ presence, and their positions will become clear when these structurally related 
compounds are tested. 
Chapter III. Results and Discussion 
 
 
 
81 
N
H
193
N
H
147 (I3C)
OH
N
H
208
H2N
N
H
221
O
N
H
Me
161
MeO
N
H
189
O
O
Me
HO
OH
OH
Resveratrol
N
H
HO
HO
OH
193 and Resveratrol's
structures superimposed
 
Figure 30: Diagram showing the structures of the tested indoles and the structural similarity between 
resveratrol and compound 193 (box). 
In this regard, the dose response curves of cisplatin, resveratrol, and the various 
indoles mentioned above were plotted against the 1321N1 and U87MG cell lines using the 
MTS cell proliferation assay, wherein both these cell lines were exposed to different 
concentrations of the compounds for 48 h.  
As shown in Figure 31 and Figure 32, the IC50 value of cisplatin was 11 ±2 µM on 
the 1321N1 cell line and 310 ±4 µM on the U87MG cell line. The results also showed that 
whilst compound 147 (I3C) had modest activity [IC50 = 309 ± 2 μM (1321N1) and 670 ± 2 
μM (U87MG)], compound 193 did not reach its IC50 over the same time frame (48 h) but 
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only reached a maximum growth inhibition of 7 % (U87MG) at 400 μM, however, 
compound 193 was not able to inhibit the growth of the 1321N1 cell line at all.  
 
 
Figure 31: Various indoles tested in comparison with cisplatin and resveratrol on the 1321N1 cell line after 
treatment for 48 h. The data points are means of 4 repeats and the error bars represent ±SD.  
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Figure 32: Various indoles tested in comparison with cisplatin and resveratrol on the U87MG cell line after 
treatment for 48 h. The data points are means of 4 repeats and the error bars represent ±SD.  
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In support of these results, studies increasingly indicate that dietary I3C prevents the 
development of oestrogen-enhanced cancers including breast, endometrial and cervical 
cancers (Brew et al., 2009; Auborn et al., 2003; Mori et al., 2001). For example, the cell 
division cycle 25A (Cdc25A) phosphatase is overexpressed in a variety of human cancers 
and I3C induces degradation of Cdc25A, and arrest of the G1 cell cycle, which inhibits the 
growth of breast cancer cells (Wu et al., 2010). Recent studies showed that the serine124 
site of Cdc25A, which is related to cyclin-dependent kinase 2 (Cdk2), is required for I3C-
induced degradation of Cdc25A in breast cancer cells, and that interruption of the ATM-
Chk2 pathway suppressed I3C-induced destruction of Cdc25A. CHK2 is a protein kinase 
that is activated in response to DNA damage via the ATM-Chk2 pathway and is involved in 
cell cycle arrest (Matsuoka et al., 1998) while Cdk2 is directly involved in cell cycle 
regulation (Morgan, 2007). Another recent study on MDA-MB-231 breast cancer cells 
showed that I3C induced stress fibres and peripheral focal adhesions in a Rho kinase-
dependent manner that led to an inhibition of motility in human breast cancer cells. I3C 
significantly decreased the in vitro migration of these cells and therefore it may be a useful 
agent in reducing the metastatic spread of tumours (Brew et al., 2009). 
An unexpected, yet reproducible and statistically significant result also evident from 
these results (Figure 32) is that compound 208 appears to induce cell proliferation on the 
U87MG glioma cell line (compared to control cells), but is inactive on the 1321N1 cell 
line, an intriguing feature which was not pursued here, but may be worth following up in 
the future. Compounds 189, 161 and 221 were found to be inactive against both cell lines. 
Based on the results in Figure 31 and Figure 32, whilst bearing in mind the 
observed importance of both compound 147 (I3C) and the 2-phenyl group in indoles 
(Gastpar et al., 1998), it was of interest to know whether or not the preparation of hybrid 
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structures of compounds 147 (I3C) and 193, thus generating 223a and 209 (Figure 33), 
would result in improved activity against these cell lines in comparison with the activities 
of indoles 147 (I3C) and 193 themselves. In the event, indoles 223a (Leete, 1959) and 209 
(Snape, 2008) were prepared as previously reported, and both were subjected to the same 
assay as indoles 147 (I3C) and 193 above. Such compounds would introduce hydroxyl 
groups into these molecules, a structural feature which appears to be important in the 
activity of resveratrol (when compared to compound 193) and 147 (I3C) itself (Figure 30). 
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Figure 33: Chemical structures of indole-3-carbinol (147 (I3C), a 2-arylindole (compound 193) and their 
proposed structural hybrids (compound 223a and 209). 
In addition, two further analogues, compounds 223 (So et al., 2007) and 250 were 
prepared by synthetic chemists in the Snape research group (Prabhu et al., 2013a) and also 
included as test compounds to determine if there was any influence induced by the 
hydroxyl group on activity. 
Hybridise 
209 is a hydroxy 
193 derivative 
223a is a 2-aryl 
I3C derivative 
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For example, a direct comparison between compounds 223a and 147 (I3C) or 193, 
and between 209 with 193 would allow the importance of the inclusion of the hydroxyl 
group to be made. Moreover, a direct comparison between compounds 223a and 209 will 
enable the importance of the position of the hydroxyl group to be made. Furthermore, the 
readily prepared compound 223 will allow a comparison to be made between the hydroxyl 
group (in compound 209) and the methoxy group (in compound 223), i.e. is the –OH 
important for hydrogen bonding donation or will oxygen alone suffice? Similarly, 
comparison between compounds 208 and 250 will enable the importance of –NH2 vs.–
NHAc to be made. All the above-mentioned novel compounds were tested in comparison 
with cisplatin as the positive control (section 3.2.1.1). 
3.2.4 Testing the hybrid compounds and their analogues on glioma cell 
lines 
The newly synthesised hybrid compounds and their analogues (section 3.2.3 above) 
were tested on the 1321N1 and U87MG glioma cell lines. As before, dose response curves 
on these cell lines using compounds 209, 223a, 223, 250 and 193 were plotted using the 
MTS cell proliferation assay, wherein the cell lines were exposed to different 
concentrations (200 µM, 400 µM, 750 µM and 1000 µM) of these compounds for 48 h.  
As shown in Figure 34 and Figure 35, both the hybrid compounds (209 and 223a) 
were more active than compounds 147 and 193, in both cell lines. Compounds 193 and 223 
were found to be inactive, whilst the IC50 values were reached at concentrations of 586 ±4 
µM and 396 ±4 µM (compound 209) and 111 ±1 µM and 176 ±1 µM (compound 223a) 
over 48 h on the 1321N1 and U87MG cell lines respectively. Compound 250 reached its 
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IC50 value at concentrations of 695 ±4 µM and 600 ±2 µM on the 1321N1 and U87MG cell 
lines respectively, table 5 summarises these results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Indoles tested on the 1321N1 cell line for 48 h. The data points are means of 4 repeats and the error 
bars represent ±SD.  
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Figure 35: Indoles tested on the U87MG cell line for 48 h. The data points are means of 4 repeats and the 
error bars represent ±SD.  
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Table 5: Showing the IC50 values of cisplatin, and the indoles against the two different cell lines after being 
exposed for 48 h using the MTS assay. The values shown are the standard deviations of four repeats. 
 MTS assay IC50 values 
Entry Compounds 
1321N1 
(µM) 
U87MG 
(µM) 
1 147(I3C) 309±2 670±2 
2 223 >1000 >1000 
3 223a 111±1 176±1 
4 209 586±4 396±4 
5 193 >1000 >1000 
6 250 695±4 600±2 
7 221 >1000 >1000 
8 Cisplatin 11±2 310±4 
 
The compounds with IC50 values > 1000 µM were considered to be inactive in these assays. 
3.2.5 The instability of compound 223a in acidic media 
As shown in section 3.2.4 (Figure 34 and Figure 35), compound 223a is one of the 
most potent indoles tested against these cell lines. Unfortunately, it proved to be unstable 
under acidic conditions, and such behaviour is well documented for similar structures 
(Bradlow, 2008; Rogan, 2006; Weng et al., 2008), as such, this inherent instability did not 
justify further investigation here and therefore it was not used in future experiments. As 
Figure 36 shows, upon exposure to acid, it is known that compound 147 (I3C) loses a 
molecule of water to give the positively charged species shown.  Thus, in the same vein, a 
similar chain of events is likely to occur in compound 223a, however, in this case, the 
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addition of the 2-aryl ring in compound 223a may cause further instability by increasing the 
conjugation of the vinylogous hemiaminal of compound 147 (I3C), and thus increasing the 
stability of the acid degradation products and rendering the compound more acid sensitive. 
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Figure 36: Diagram depicting the acid instability of compound 147 (I3C) and the analogous structure for the 
presumably more stable acid-degradation product from compound 223a. 
 An interesting feature of the acid instability of compound 147 (I3C) is that the 
resulting positively charged species can dimerize to form a compound known as 3,3'-
diindolylmethane (DIM), the compound which appears to be the biologically active species 
of I3C. However, it is unlikely that such dimerization can occur with compound 223a due 
to the bulky phenyl ring in the 2-position preventing two molecules joining together. 
3.3 Structure-activity-relationship of compound 209 with 
its analogues 
As shown above (section 3.2.4), compound 209 was found to be the most active, 
stable indole tested, and in the event of having to halt the further evaluation of compound 
223a due to its instability issues, the aim now was to determine preliminary structure-
activity-relationships of compound 209 and try to determine how it may be exerting its 
effect. Research has shown that in general, 2-arylindoles (Figure 37) are known to be active 
in a wide range of therapeutic areas (Lal and Snape, 2012), therefore, the structure-activity-
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relationship screening was categorised into two main groups: indoles without the 2-aryl 
group and indoles with the 2-aryl group. 
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HO
 
Figure 37: Diagram showing the structure of a generic 2-arylindole (left) and the potent compound (209, 
right). 
3.3.1 Indoles without the 2-aryl group 
As shown above in Figure 31 and Figure 32, compounds 161 and 189, which lack a 
2-aryl group, are completely inactive. The exception being compound 147 (I3C), which is 
known to possess anti-cancer activity (Safe et al., 2008; Bradlow, 2008; Firestone and 
Bjeldanes, 2003). That said, of the three compounds which lack a 2-aryl group, compound 
147 (I3C) uniquely possesses a hydroxyl group, a functional group which appears to be 
important when the activities of resveratrol and compounds 209 and 223a are considered, 
all of which contain at least one hydroxyl group. Based on this, it was hoped that it would 
be possible to ascertain how important the –OH group was to the activity seen here. A 
recent study on melanoma cells showed that doxycycline, a member of the tetracycline 
antibiotics group induced intra-cellular ROS generation and led to c-Jun N-terminal kinase 
(JNK) activation and cellular apoptosis (Shieh et al., 2010). Observations regarding its 
structure indicated that doxycycline has multiple –OH groups and that such groups may be 
playing an important part in inducing cell death. Previous studies have also shown that 
various naturally occurring dietary compounds like capsaicin, gingerol, 6-paradol and 6-
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dihydrocapsaicin protect against experimentally-induced mutagenesis and tumourigenesis 
(Surh, 1999), and that the anti-cancer effects of these compounds is thought to be due to the 
common factor that all of them possess –OH groups, and thus this feature may be one of the 
reasons for their shared anti-cancer activity. 
3.3.2 Indoles with the 2-aryl group 
In order to test this hypothesis, analogues of compound 209 were purchased or 
prepared which possessed the 2-aryl group, but lacked the –OH group, in order for them to 
be screened in the MTS assay so as to determine if this group was important for anti-cancer 
activity (Figure 38). Compound 193 lacks any substituent on the 2-aryl group and was 
found to be inactive, as already shown, suggesting that in this case, the –OH may be 
important for activity. Similarly, to further test its importance, analogues 223 and 221, 
which also both lack the –OH group, were prepared (223) by the members of the Snape 
research group or bought (221), and tested. In the case of compound 223, oxygen was 
present on the 2-aryl group, but not as an –OH group, but rather as an –OMe group. In 
contrast, compound 221 possesses an aldehyde on the indole ring but no substituents on the 
2-aryl group. Upon testing, both of these compounds were found to be inactive, again 
suggesting that the –OH group may be essential for activity to exit, either on the ring (as 
with 209 compared to 193) or on the indole ring (as with I3C compared with 221). 
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Figure 38: Diagram representing the analogues of compound 209 without the aryl–OH group, but with the 2-
aryl ring. 
Further analogues of 209 were obtained to ascertain whether an –NH2 group (an 
amine) on the benzene ring was as active as the –OH group of compound 209. These 
analogues (208 and 250) were also found to be inactive, or only active at a very high 
concentration (IC50 value of compound 250 is > 600 µM) indicating, once again, that the –
OH group seems to be important for their anti-cancer activity in some way. 
As alluded to earlier, compound 208 appeared to induce cell growth on the U87MG 
cell line, however, upon its derivatization to form an acetamide group (-NHAc, compound 
250), the compound no longer induced cell growth, but was active at rendering the cells 
non-viable at very high concentrations.  
In Figure 31 and Figure 32, compound 221 was shown to be inactive, therefore it 
was decided to reduce its aldehyde to the primary alcohol, thus generating the hybrid 
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compound 223a (Figure 33). The rationale for this decision was that unlike 221 and 193 
which had no –OH group on the benzene ring (and were therefore shown to be inactive), 
223a had an –OH group that was not on the benzene ring, but was in fact in a similar 
position to that of indole-3-carbinol’s –OH, group and that compound was found to be 
active (IC50 value of indole-3-carbinol on the 1321N1 cell line = 309 µM and U87MG = 
670 µM). Clearly, the –OH group was having a large influence on the activity of these 
indoles.  
The results of compound 223a, as determined by the MTS assay, show that it is 
active on both the 1321N1 and U87MG cell lines suggesting, once again, that the –OH 
group was very important, but that it does not necessarily need to be attached directly to the 
benzene ring as in compound 209 (IC50 value of compound 223a on the 1321N1 cell line = 
111 µM and U87MG = 176 µM). However, it is important to note that whilst all of the 
initial intermediates tested contain an aromatic –OH group, they were all inactive (section 
3.2.2) further corroborating that the indole nucleus, as a whole, appears to be important. 
This suggestion is supported by the fact that indoles appear to be privileged in their ability 
to possess activity in a number of therapeutic areas (Horton et al., 2003; Lal and Snape, 
2012). Further structure-activity-relationship studies would be the subject of future work on 
this project to attempt to optimise activity further still. 
 Having discovered potentially new lead cytotoxic indoles against the glioma cell 
lines (1321N1 and U87MG), it was essential to determine the mechanism of action of the 
more active (and stable) indole (compound 209) in the hope that the biological target(s) 
identified could be used to help with future rounds of lead development by incorporating in 
silico modeling. Preliminary insights into their mechanism of action were gleaned from the 
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structure of the active compounds, since it was insightful that compounds 147, 209 and 
223a were active, yet analogues such as 193, 223 and 221 were not; the hydroxyl group was 
evidently having an effect. Furthermore, a previous study showed that the phenol group of a 
related indole was reported as having a large influence on the activity of similar compounds 
against breast cancer cell lines MDA-MB 231 and MCF-7 (Gastpar et al., 1998), further 
indicating that the –OH group may be important. Additionally, a recent study has shown 
that 2-(2,4-dihydroxyphenyl)-8-hydroxy-1,4-naphthoquinone, a derivative of an aromatic 
compound, juglone, which possesses hydroxyl groups, showed significant anti-cancer 
activity by inducing apoptosis on immortalised human glioma cell line GLI36 and in a 
primary human glioblastoma cell culture (Zagotto et al., 2011).  
In the compounds studied herein, it was assumed that such a difference in activity 
between the compounds possessing a hydroxyl group and those that did not, could not be 
due to differences in hydrogen-bonding, and therefore the hydroxy or phenoxy groups in 
these compounds may be responsible for the observed cell death in another way.   
Recent and previous studies have shown that hydroxy and phenoxy containing 
compounds may act as anti-oxidants as well as pro-oxidants under certain conditions 
(Fujisawa et al., 2005; Iwasaki et al., 2011). For example, it is known that certain phenoxy 
compounds act as anti-oxidants at low concentrations, whereby they are used to scavenge 
free radicals in the cell, yet they are able to cause cell death at high concentrations, due to 
themselves forming cell-damaging free radicals. In addition, such a switch can also occur in 
the presence of Cu2+ whereby the chelated compounds are able to induce ROS production 
and subsequently cause DNA damage (Iwasaki et al., 2011). Factors which may need to be 
taken into account when the mechanism of action of compound 209 is being considered. 
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It has been proposed that ortho-dihydroxy groups that can chelate Cu2+ induce the 
greatest pro-oxidant activity (Brown and Kelly, 2007), and a recent study showed that 
compounds such as ferulic acid, quinic acid and resveratrol did not induce ROS by Cu2+, 
because they have no ortho-dihydroxy groups (Iwasaki et al., 2011). A result which also 
agrees with the data of this current study (section 3.5.1), in which resveratrol took more 
than 24 h to cause cells to become non-viable, possibly suggesting that this compound was 
acting via a different mechanism other than simply generating ROS at the concentrations 
used. 
3.4 The importance of phenols and phenolic fragments 
As shown throughout this thesis so far, it is known that certain indoles possess 
potent anti-cancer activity which is of great interest to the pharmaceutical industry, and 
numerous specific derivatives are reported annually (Shankar and Srivastava, 2012). The 
synthesis and reactivity of these indole derivatives has been a topic of research importance 
for more than a century, and the primary reason for this continued interest is the wide range 
of biological activity found among indoles (Sharma et al., 2010; Lal and Snape, 2012). 
Research has also shown that sterically hindered phenolic motifs in indoles could give rise 
to added anti-oxidant properties, and such sterically hindered phenols also constitute 
structural fragments of a number of non-indole drugs too (Nugumanova et al., 2007). 
Therefore, compounds derived from both indoles and sterically hindered phenols may have 
promising biological activity, as has been shown here. 
 Research by others has also shown that phenols may directly contribute to high 
anti-proliferative and pro-apoptotic activity (Marian et al., 2004; Zagotto et al., 2011). For 
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example, carnosic acid, a rosemary phenolic compound, has been shown to display anti-
cancer activity and induce ROS mediated apoptosis in human neuroblastoma IMR-32 cells 
(Tsai et al., 2011). Their results also suggested that down-regulation of the anti-apoptotic 
Bcl-2 protein occurred in cells treated with carnosic acid. This effect was accompanied by 
increased activation of p38 and by decreased activation of extracellular signal-regulated 
kinase (ERK) as well as activation of JNK (Tsai et al., 2011).  
Furthermore, curcumin, the principal curcuminoid of the popular Indian spice 
turmeric, is known to show high anti-tumour activity on malignant cells (Tuttle et al., 2011; 
Youssef and El-Sherbeny, 2005). The role of curcumin in inhibiting malignancy can also be 
due to its anti-oxidant activity (Nagabhushan M and SV, 1987), and Sreejayan and Rao 
have reported that the phenolic hydroxyl and methoxy groups on the phenyl ring, and the 
1,3-diketone system are the two most important structural features that contribute to its 
anti-oxidant properties (Sreejayan and Rao, 1996; Sreejayan and Rao, 1997; Jovanovic et 
al., 2001; Sun et al., 2002; Anto et al., 2002). Taken together, the importance of the indole 
nucleus and phenolic compounds suggests that the potent compound 209 used in this study 
(Figure 33), which possesses a phenolic group attached to indole, may be partly responsible 
for its activity. 
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3.5 Time course studies of compound 209. 
3.5.1 Time course study using the MTS assay 
During the MTS cell viability assay, at relatively high concentrations, visual 
morphological changes were observed to take place on the cells treated with compound 
209, an effect which was detected within the first hour of treatment. Based on this rapid 
result, a time course study was performed to determine the minimum time necessary for 
compound 209 to cause the cells to become non-viable (as determined by the MTS assay). 
In the event, as shown in Figure 39 and Figure 40, the cytotoxic effect of compound 209 
(750 µM and 1000 µM) starts 1.5 h after the treatment on the 1321N1 and U87MG cell 
lines. 
As highlighted in Figure 30 (box), the structural similarity between resveratrol and 
compound 193 is high. Based on this structural overlay, compound 209 has even greater 
similarity to resveratrol than compound 193 due to the presence of the hydroxyl group on 
the aryl ring in compound 209, therefore resveratrol was also used in this time course study, 
however, resveratrol was only used on the 1321N1 cell line since U87MG was found to be 
resistant to resveratrol (Figure 41).  
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Figure 39: 1321N1 cell line treated with compound 209 at two different concentrations. 
 (A) 1000 µM and (B) 750 µM at various time points where it can be seen that the cytotoxic effect starts after 
1.5 h after treatment. The data points are means of 4 repeats and the error bars represent ±SD. 
A 
 
B 
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Figure 40: 1321N1 cell line treated with resveratrol at two different concentrations. 
 (A) 1000 µM and (B) 750 µM at various time points. It can be clearly seen that there is no immediate 
cytotoxic effect like that observed with compound 209. The data points are means of 4 repeats and the error 
bars represent ±SD. 
A 
 
B 
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The time course study for resveratrol (Figure 40) suggested that it required more 
than 24 h to display its effects, a result which is in contrast to compound 209 which 
exhibited up to 40 % cell death within 2 h on both cell lines (Figure 39 and Figure 41). This 
suggests that the mechanism of action of compound 209 is different to that of resveratrol, 
despite being structurally comparable and both possessing phenolic group(s), results which 
may indicate that the entire structure (and possibly the indole nucleus itself), as a whole, 
may be required for quick cell death to occur. Despite their structural similarities, the 
differing time taken for resveratrol and compound 209 to exert their anti-cancer effects, 
suggests that their mechanisms of action must be different. 
As seen here in glioma cells, previous research has showed that resveratrol induces 
cell death within 24 h in ovarian cancer cells, and that the mitochondrial release of 
cytochrome c, formation of the apoptosome complex, and caspase activation was observed 
after treatment with resveratrol (Opipari et al., 2004). Remarkably, even with such 
molecular features of apoptosis, analysis of resveratrol-treated cells by light and electron 
microscopy revealed morphological and structural changes indicating autophagy, rather 
than apoptosis in these ovarian cancer cells (Opipari et al., 2004). This may indicate that 
resveratrol can induce cell death through two distinct pathways, but that both of these 
pathways are not able to induce the quick cell death seen by treatment with compound 209 
on the glioma cells. 
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Figure 41: U87MG cell line treated with compound 209 at two different concentrations. 
 (A) 1000 µM and (B) 750 µM at various time points where it can be seen that the cytotoxic effect starts after 
1.5 h after treatment. The data points are means of 4 repeats and the error bars represent ±SD. 
A 
 
B 
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3.5.2 Time course study using the trypan blue exclusion test 
In addition to the onset of cell death occurring after 1.5 h on both cell lines, as 
indicated with the MTS assay (section 3.5.1), a time course study using trypan blue was 
also performed to find out the time required by compound 209 to cause membrane lysis, a 
feature indicated by the cell being stained blue, signifying cell death has occurred (section 
2.3.3).  
In the event, membrane lysis (as indicated by trypan blue staining) was observed on 
both 1321N1 [Figure 42 D] and U87MG [Figure 43 D] cell lines after 1.5 h of treatment 
with compound 209. Representative images from one of three experiments yielding similar 
results are shown. 
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 Figure 42: Images of human glioma cells 1321N1 showing membrane lysis (as indicated by trypan blue 
staining) after treatment with compound 209 (1000 µM) at different time points at 20X magnification.  
A) 15 min (0.25 h) B) 45 min (0.75 h) C) 75 min (1.25 h) D) 90 min (1.5 h) E) 120 min (2 h) F) control 
untreated cells. 
 
Figure 43: Images of human glioma cells U87MG showing membrane lysis (as indicated by trypan blue 
staining) after treatment with compound 209 (1000 µM) at different time points at 20X magnification.  
A) 15 min (0.25 h) B) 45 min (0.75 h) C) 75 min (1.25 h) D) 90 min (1.5 h) E) 120 min (2 h) F) control 
untreated cells. 
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As can be seen from Figure 42 and Figure 43, cell death (i.e. cells are stained blue) 
was observed with 1000 µM of compound 209, between 90-120 min (D and E in Figure 42 
and Figure 43), data which supports the results observed with the MTS assay (section 
3.5.1). Together, these time course studies suggest that at high concentrations, compound 
209 has a rapid effect on cell viability which may be an indication of necrosis. This 
suggests that the concentrations of compound 209 may play an important role in deciding 
the type of cell death pathway to be followed, as has been observed for other phenolic 
compounds which are either anti-oxidant (at low concentrations) or pro-oxidants (at high 
concentrations) (Iwasaki et al., 2011; Fujisawa et al., 2005). 
3.6 The activity of various indoles on the 1321N1, 
U87MG and SVGp12 cell lines (2 h) 
Up until this point the best compounds discovered were indoles 209 and 223a, a 
feature which was temporarily put down due to the presence of the hydroxyl group in these 
structures, a feature which they share with the active compound 147 (I3C). Contrastingly, it 
was possible to use indoles 193 and 223 as negative controls, since both had the hydroxyl 
group either missing or masked, and are consequently inactive, a feature which suggests 
that the hydroxyl group is important. Having established an apparent rapid mechanism of 
action for indole 209 (section 3.5), compounds 209, 193 and 223 were further tested on the 
1321N1, U87MG and SVGp12 cell lines for 2 h. The previous time course study using 
compound 209 on the glioma cell lines (section 3.5) showed that this indole exhibited its 
anti-cancer activity within 2 h. The following study was therefore performed to determine 
their IC50 values at the 2 h time point, and to see whether they all act and exhibit an effect, 
in a similar way as seen at the 48 h time point (Figure 34 and Figure 35). As seen 
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previously in Figure 31 and Figure 32, cisplatin was used as a positive control, whereas, in 
this 2 h study cisplatin was not used because it needs at least 48-72 h to exert its cytotoxic 
effect (Shervington et al., 2009; Pisanu et al., 2014). The SVGp12 cell line (non-cancerous) 
was also introduced in this study to determine whether compound 209 was specific to 
cancer cells or whether it exhibits cytotoxicity on all cell types, including non-cancerous 
ones. 
Dose response curves of compounds 209, 193 and 223 on 1321N1, U87MG and 
SVGp12 cell lines were plotted using the MTS cell proliferation assay, wherein the cell line 
was exposed to different concentrations of these compounds for 2 h. The active compound 
209 and two inactive compounds (223 and 193) were chosen to be tested on the above cell 
lines according to the results obtained in section 3.2.4. Compound 193, being completely 
inactive on the 1321N1 and U87MG cells lines, was used as a negative control, whereas 
compound 223, which was only weakly active and therefore did not reach the IC50 value, 
was also included. Compound 250 was not used in this study as its IC50 value (> 600 µM 
on both the cell lines) was considered too high compared to compound 209.  
In the 2 h time course experiments (Figure 44 and Figure 45), IC50 values of 996 ±5 
µM and 700 ±3 µM were obtained for compound 209 on the 1321N1 and U87MG cell lines 
respectively (table 6). In addition, as shown in Figure 46, the IC50 value of compound 209 
was 750 ±2 µM on the SVGp12 cell line. As expected, compound 223 was only weakly 
active and did not reach the IC50 value, whereas compound 193 was completely inactive 
(table 6). 
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Table 6: Showing the IC50 values of indoles against the two different cell lines after being exposed for 2 h 
using the MTS assay. The values shown are the standard deviations of four repeats. 
 MTS assay IC50 values 
Entry Compounds 1321N1 (µM) U87MG (µM) SVGp12 (µM) 
1 209 996 ±5 700 ±3 750 ±2 
2 223 >1000 >1000 >1000 
3 193 >1000 >1000 >1000 
Those compounds with low activity (i.e. less than 10 % cell death) at a concentration of 
1000 µM were considered to be inactive in these assays. 
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Figure 44: Indoles tested on the 1321N1 cell line for 2 h using the MTS assay. The data points are means of 4 
repeats and the error bars represent ±SD.  
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Figure 45: Indoles tested on the U87MG cell line for 2 h using the MTS assay. The data points are means of 4 
repeats and the error bars represent ±SD.  
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Figure 46: Indoles tested on the SVGp12 cell line for 2 h using the MTS assay. The data points are means of 4 
repeats and the error bars represent ±SD.  
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3.6.1 Corroborative study of compound 209 using the ATP assay. 
Up to this point the cytotoxicity of the test compounds had only been examined 
using the MTS assay, however, before further mechanistic studies were carried out, it was 
felt prudent to corroborate these results using a second cell viability assay.  
During these experiments, dose response curves of compounds 209, 193 and 223 
were obtained, on both the 1321N1 and U87MG cell lines, using an ATP cell viability 
assay (section 2.3.2). The cell lines were exposed to different concentrations of these 
compounds for 2 h, wherein compounds 193 and 223 were included as negative controls, as 
per the results obtained from the MTS assay (section 3.2.4). 
Table 7 outlines the IC50 results of the ATP assay on both the cell lines vs. the test 
compounds. 
Table 7: Showing the IC50 values of the indoles tested against the two different cell lines after being exposed 
for 2 h using the ATP assay. The values shown are the standard deviations of four repeats. 
 ATP assay IC50 values 
Entry Compounds 
1321N1 
(µM) 
U87MG 
(µM) 
1 209 1000 ±4 878 ±3 
2 223 >1000 >1000 
3 193 >1000 >1000 
Those compounds with low activity (i.e. less than 10 % cell death) at a concentration 
of 1000 µM were considered to be inactive in these assays. Unlike the MTS assay, the ATP 
assay can measure cells as low as 4 cells per sample, in contrast to MTS assay which can 
only detect samples containing more than 1000 cells, as such, the ATP assay is highly 
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sensitive (Petty et al., 1995) and thus is considered a more accurate assay and thus can be 
used for corroborating the results obtained using the MTS assay. Despite this increased 
accuracy, the ATP assay was not used throughout the whole of my PhD project because, 
not only is it a more expensive protocol, it is also more time consuming compared to the 
MTS assay. As such, the use of the MTS assay allowed quick and inexpensive data to be 
obtained, thus enabling structure-activity data to be more easily achieved.  
The data obtained from the ATP assay (table 7) gave a similar pattern of activity for 
both the cell lines to that of the MTS assay, thus enabling me to confidently trust the results 
obtained throughout by the MTS assay. Although the activity obtained with the ATP assay 
is only modest, the values in table 7 are IC50s, showing that 50 % cell death had occurred at 
the concentration quoted in the table. 
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Section B: Preliminary investigation into the 
mechanism of action of the most potent indole 
3.7  Detection of Reactive Oxygen Species (ROS). 
3.7.1 Possible cellular mechanism of action of compound 209 
It was important to determine the cellular mechanism(s) via which the most potent 
compound could induce cell death as this would help in narrowing down the cellular 
processes which is active indole may be targeting. The effects of compound 209 were rapid 
(2 h) as opposed to other conventional drugs which require at least 48 h of treatment to 
induce cell death.  
Different classes of anti-cancer drugs act via differing mechanisms to induce cell 
death; these include: apoptosis, derangement in calcium homeostasis, cell cycle arrest and 
alteration in gene expressions (Pratheeshkumar et al., 2012). The challenge here was to find 
a cell death mechanism which was as quick as that observed (i.e. within 2 h). Since the 
above mentioned cell death mechanisms cannot complete their cycle in such a short time 
span of 2 h, it was hypothesised that such quick cell death might be mediated by oxidative 
stress [generation of excessive reactive oxygen species (ROS)]. For example, in a recent 
study on the U87MG cell line, it has been observed that basal ROS levels can increase to 
toxic levels within 30 min following treatment with β-lapachone, a natural naphthoquinone 
compound (Park et al., 2011). 
Moreover, another separate study showed that oncogenic transformation of ovarian 
epithelial cells with a human plasmid [H-RasV12] caused elevated ROS levels within 5 h 
and rendered the malignant cells highly sensitive to beta-phenylethyl isothiocyanate 
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(PEITC, a chemopreventive agent found in abundance in watercress), a process which 
effectively disabled the glutathione anti-oxidant system and caused severe ROS 
accumulation preferentially in the transformed cells due to their active ROS output. This 
excessive ROS production caused oxidative mitochondrial damage and inactivation of 
redox-sensitive molecules (Trachootham et al., 2006). Such precedent prompted a new 
study in this project directed at identifying if any ROS mediated cell death was occurring in 
the glioma cell lines by the most suitable compound identified by the MTS assay (section 
3.2.4). Therefore, in this regard, both the glioma cell lines (1321N1 and U87MG) were 
studied for ROS generation post-treatment with the most potent novel (and stable) indole, 
compound 209. 
3.7.2 Confocal microscopy using an “Image-iT LIVE Green Reactive 
Oxygen Species Detection Kit”. 
This study was performed to help understand the possible mechanism behind the 
apparent quick cell death caused by compound 209 on the 1321N1 glioma cell lines. An 
Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit was used to detect the 
reactive oxygen species in the 1321N1 and the glioma cell lines. The assay is based on the 
compound, carboxy-H2DCFDA, a reliable fluorogenic marker for ROS in live cells, 
whereby oxidatively stressed cells fluoresce when labelled with the carboxy-H2DCFDA 
dye provided in the kit. The results can then be observed by either confocal microscopy 
(qualitative only) or by flow cytometry (quantitative). 
Initial qualitative data was obtained using confocal microscopy which was used to 
visualise any fluorescence produced, before moving on to use flow cytometry to quantify 
the amount of fluorescence produced. This additional observational step was required 
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because a previous kit ordered for detecting ROS, for some unknown reason, did not work. 
Therefore, in all future experiments with this kit, to ensure that the assay was working 
properly, it was performed using a confocal microscope as well using the positive control, 
tert-butyl hydroperoxide (TBHP), supplied by the assay manufacturing company. For 
conformation of the assay working properly, the 1321N1 cell line was used (Figure 47). 
Once it was confirmed that the assay was working, all future experiments were then 
performed on a flow cytometer so that the amount of fluorescence produced could be 
quantified.  
During the experiment, cells were thoroughly washed at each step to prevent 
background staining and were imaged immediately and fluorescence was observed. The 
results with compound 209 (500 µM), for 1 h, suggested that the cells were under oxidative 
stress during this time, as indicated by the increased levels of fluorescence visualised as 
compared to the control cells (Figure 47). The positive control used in this experiment was 
tert-butyl hydroperoxide (TBHP) (100 µM) which is a common inducer of ROS 
(Bhattacharya et al., 2011) and was suggested and provided by Invitrogen Ltd.  
It is known that ROS generation is instantaneous and at optimum levels within 2 h, 
but then reduces considerably after 24 h, as has been shown before by (Rogalska et al., 
2011), and thus the conditions used here were focussed on a 1 h timeframe. 
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Figure 47: Confocal acquisitions of human glioma cell line 1321N1 at 40X magnification after 1 h of 
incubation with Image-iT ™ LIVE Green Reactive Oxygen Species Detection Kit and compound 209. 
 (A) 1321N1 control untreated cells. (B) 1321N1 cells treated with positive control [(tert-butyl hydroperoxide 
(TBHP) (100 µM)]. (C) 1321N1 cells treated with compound 209 (500 µM). Representative data from one of 
three experiments yielding similar results are shown. 
The concentration used in this study was not greater than 500 µM because anything 
greater than that caused the cells to detach making it difficult for confocal imaging to take 
place. One possible reason the cell detachment caused may have been due to cells being in 
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a necrotic stage (as witnessed by membrane lysis, section 3.1.2) since the trypan blue 
exclusion test indicated membrane lysis occurs within 1.5 h of treatment with compound 
209 at high concentrations.  
3.7.3 Flow cytometry analysis using Image-iT LIVE Green Reactive 
Oxygen Species Detection Kit. 
3.7.3.1 Treatment with the test compounds for 1 h  
The ROS data accrued to this point was merely qualitative, however, in order to 
quantify the fluorescence produced in the cells, both the 1321N1 and U87MG cell lines 
were analysed using flow cytometry. The cells were treated with compound 209, 
compounds 193 and 223 (used as negative controls, according to the results in section 
3.2.4) and a positive control [tert-butyl hydroperoxide (TBHP)] for 1 h followed by 
incubation with the dye as per the provided protocol (section 2.5.2). On analysing the 
results (FACSAria machine, BD Biosciences), a significant shift in the peak, which 
indicates an increase in the amount of fluorescence in the cells treated with compound 209, 
was observed when compared to the control cells; such results indicate that excessive 
generation of ROS is taking place, i.e. the cells are under oxidative stress (Figure 48D and 
Figure 49D).  
The cell lines 1321N1 and U87MG showed 94 % and 79 % ROS positive cells 
respectively, when treated with compound 209 for 1 h suggesting that this indole generates 
substantial amounts of ROS. The percentage of ROS positive cells was calculated by 
comparison to the control cells, thus eliminating the basal levels of ROS which are present 
in each of the cells (table 8). 
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Table 8: The percentage of ROS positive cells when treated with compounds 209, 193, 223 and TBHP for 1 h. 
Carboxy-H2DCFDA staining intensity was quantified by flow cytometry and the following values are the 
means of 3 repeats. (t-test, P < 0.05 for compound 209, SD = Standard deviation). 
                        Cell lines    
Compounds 
1321N1 (%) U87MG (%) 
TBHP (positive ctrl) 11 ± 2.95 SD 11 ± 0.5 SD 
193 (negative ctrl) 3 ± 0.25 SD 1 ± 0.1 SD 
223 (negative ctrl) 9 ± 4.78 SD 3.5 ± 0.25 SD 
209 (test compound) 94 ± 2.08 SD 79 ± 6.5 SD 
Previous and recent studies have shown similar results where ROS-mediated cell 
death occurred (Zhang et al., 2014; Zhu et al., 2014; Park et al., 2011). For example, a 
recent study showed that sodium arsenite induced ROS-dependent autophagic cell death in 
pancreatic β-cells (Zhu et al., 2014). Another separate study also showed that gambogic 
acid, the main active component of gamboge resin, induced ROS-mediated autophagy in 
colorectal cancer cells (Zhang et al., 2014). Such literature supports the results obtained in 
the current study whereby the cell death which has been observed was mediated by ROS. 
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Figure 48: 1321N1 cells were treated with compound 209 and analogues for 1 h. 
(A) Cells + Dye (Control cells) (B) Cells treated with positive control [100 µM tert-butyl hydroperoxide 
(TBHP)] (C) Cells treated with compound 193 (500 µM) (D) Cells treated with compound 209 (500 µM) (E) 
Cells treated with compound 223 (500 µM). Carboxy-H2DCFDA staining intensity was quantified by flow 
cytometry. Representative data from one of three experiments yielding similar results are shown. 
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Figure 49: U87MG cells were treated with compound 209 and analogues for 1 h. 
(A) Cells + Dye (Control cells). (B) Cells treated with positive control [100 µM tert-butyl hydroperoxide 
(TBHP)] (C) Cells treated with compound 193 (500 µM) (D) Cells treated with compound 209 (500 µM) (E) 
Cells treated with compound 223 (500 µM). Carboxy-H2DCFDA staining intensity was quantified by flow 
cytometry. Representative data from one of three experiments yielding similar results are shown. 
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3.7.3.2 Dot plots for the selection of cells used in Figure 48 and 
Figure 49 
Dot plots (Figure 50) were used for the assay so that a suitable population could be 
selected for fluorescence analysis, and cell debris could be discounted by drawing a gate 
around the population of interest. The manner in which the light bounces off each cell gives 
information about the cell’s physical characteristics. Light scatter or fluorescence data are 
captured, spectrally filtered and directed to the suitable photodetectors for converting into 
electrical signals. For example, light scatter is collected at two angles: Forward Scatter 
(FSC) and side scatter (SSC). FSC measures scattered light in the direction of the laser path 
and measures the size of the cell while SSC measures scattered light at 90° to the laser path 
and measures the granularity of the cell. The dot plot charts the coordinates for two 
parameters, the FSC and the SSC with each cell registered as a single dot. 
 
Figure 50: Dot plot with a gate encompassing the A) 1321N1 and  B) U87MG cell populations by scatter. 
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A gate is drawn around the population of interest, which in this case are A) 1321N1 
and B) U87MG cells. A gate or a region is a boundary drawn around a sub-population to 
isolate events for analysis or sorting. Similar gates (Figure 50) indicating the majority of 
cell populations, have been used in all of the flow cytometry experiments performed herein. 
3.7.3.3 Treatment with compound 209 at various concentrations 
In order to verify if any dose response relationship exists between treatment of the 
cell lines with compound 209 and the generation of ROS, both cell lines (1321N1 and 
U87MG) were treated with various concentrations of compound 209 (100 µM, 250 µM and 
500 µM) for 1 h, and the dose response relationship was evaluated. The maximum 
concentration of compound 209 was maintained at 500 µM which was considered 
appropriate as anything more than that caused detachment of cells during washing, which 
hampered the sample collection for flow cytometry analysis (as mentioned above). 
Compounds 193 and 223 (500 µM) were used as negative controls again since they were 
not found to be toxic in the MTS assay results (section 3.2.4), as such, their fluorescence 
should be similar to the control untreated cells. To maintain consistency, the concentration 
of compounds 193 and 223 used was also 500 µM. Cells were labelled with carboxy-
H2DCFDA dye and analysed by flow cytometry. 
The results, on both the cancer cell lines, showed that compound 209 exhibited a 
dose response with respect to ROS generation, as indicated by the largest deviation away 
from the control value when treated with 500 µM of compound 209, in comparison to cells 
treated with 250 µM and 100 µM of the same compound. More specifically, the 1321N1 
cell line showed a decrease in the percentage of ROS positive cells from 94 % at 500 µM to 
4.6 % at 100 µM whilst, the U87MG cell line showed a decrease from 79 % at 500 µM  to 
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5.1 % at 100 µM, when both cell lines were treated with compound 209 for 1 h. This data 
suggests that increasing the concentration of compound 209, increases the production of 
ROS in both the cell lines (table 9). The percentage of ROS positive cells was calculated by 
comparing them with the control cells, thus eliminating the basal levels of ROS which are 
present in each of the cells. 
Table 9: The percentage of ROS positive cells when treated with compound 209 at various concentrations for 
1 h. Carboxy-H2DCFDA staining intensity was quantified by flow cytometry and the following values are the 
means of 3 repeats. 
 
3.7.3.4 Treatment with compound 209 for 48 h 
In order to determine if the production of ROS seen here decreases over time, as 
already shown by Rogalska et al. (2011), the glioma cell lines (1321N1 and U87MG) were 
treated with compound 209 for 48 h (table 10) and the levels of ROS generation evaluated.  
For the extended time period of 48 h, concentrations of 500 µM could not be used 
since cell detachment was observed, nevertheless, at lower concentations, the 1321N1 cell 
line showed a decrease in the percentage of ROS positive cells being generated from 19 % 
at 250 µM to 3.8 % at 100 µM whilst, the U87MG cell line showed a decrease from 17 % 
at 250 µM  to 1.5 % at 100 µM. In these longer time point studies, the results indicated that 
relatively reduced levels of ROS generation had occurred in both the glioma cell lines 
(1321N1 and U87MG), compared to the previous study (table 9) in which the cells were 
                         Concentration    
Cell lines 
500  µM 250  µM 100  µM 
1321N1 94 ±2  SD 13 ± 1.75  SD 4.6 ±1.5  SD 
U87MG 79 ± 6.5  SD 35 ± 5.09  SD 5.1 ±2.15  SD 
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treated with the compound for 1 h, suggesting that ROS production is instantaneous and 
decreases over time. A previous study on a SKOV3 ovarian carcinoma cell line showed 
similar results in which ROS production decreased considerably between 24-48 h upon 
treatment with WP 631, a novel anthracycline antibiotic, when compared to a 2 h treatment 
(Rogalska et al., 2011), data which supports the results obtained from the current study. 
Table 10: The percentage of ROS positive cells when treated with compound 209 at various concentrations 
for 48 h. Carboxy-H2DCFDA staining intensity was quantified by flow cytometry and the following values 
are the means of 3 repeats. 
* At these concentrations over 48 h, the cells detach from the plate. 
As the experiments performed in this study contained a single cell population, cell 
sorting was not required. If the value obtained for the test compound was greater than that 
of the control data, it would be considered positive for ROS. The greater the difference 
between the two, the more fluorescent molecules are expressed per cell, and the more 
positive, or brighter the cell population appears, and therefore more ROS has been 
produced. Oxidative stress (ROS) was measured by comparing the fluorescence intensities 
with vehicle controls. The percentage of ROS positive cells (tables 8, 9, 10 and 11) was 
calculated by comparing it with the vehicle controls and statistical analysis was performed. 
 
                        Concentration 
Cell lines 
500  µM 250  µM 100  µM 
1321N1 -* 19 ±2.1  SD 3.8 ±1.2  SD 
U87MG -* 17 ± 3.6  SD 1.5 ±0.43  SD 
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3.7.4 Reactive oxygen species (ROS) 
Exposure to high-energy or electron-transferring chemical reactions can convert 
oxygen to various highly reactive chemical forms which are collectively designated as 
reactive oxygen species (ROS) (Apel and Hirt, 2004). Among all the known reactive 
oxygen species, the .OH free radical is possibly the most toxic, as it reacts with a number of 
biologically important molecules such as DNA, lipids or carbohydrates (Samadi et al., 
2011). The generation of ROS is unavoidable for aerobic organisms because they are the 
by-products of biochemical pathways, such as glycolysis and photosynthesis, which are 
vital for energy production and storage strategies of aerobic microbes, animals, and plants, 
and, in healthy cells, it occurs in a controlled manner (Cadenas, 1989; Apel and Hirt, 2004). 
Therefore, aerobic organisms have advanced enzymatic and non-enzymatic anti-oxidation 
mechanisms to regulate ROS and avoid oxidative stress (Marian et al., 2004). During 
conditions of oxidative stress, ROS production is significantly increased, causing 
subsequent alteration of membrane lipids and oxidation of proteins and nucleic acids (Apel 
and Hirt, 2004; Harper et al., 2004). Moreover, the oxidative damage of these biomolecules 
is related to multiple pathological events including atherosclerosis (Singh and Jialal, 2006), 
carcinogenesis (Klaunig and Kamendulis, 2004), neurodegenerative disorders (Uttara et al., 
2009) and with aging (Linford et al., 2006).  
Reactive oxygen species (ROS) that are generated from extracellular or intracellular 
sources can cause DNA damage, which in turn may activate wild-type p53 in normal cells 
and trigger a stress response, including DNA repair, to eliminate the ROS-mediated damage 
to genetic material. Nevertheless, in cancer cells which have defective p53, ROS-mediated 
DNA damage would accumulate due to a defective DNA repair function being present 
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(Trachootham et al., 2009). In cancer cells with wild-type p53, ROS-mediated DNA 
mutations or deletions may cause a loss of p53 function, resulting in a defect in DNA 
repair, which ultimately leads to an accumulation of gene mutations and deletions. This 
would lead to genomic instability resulting in the activation of oncogenes, aberrant 
metabolic stress, mitochondrial dysfunction and a decrease in anti-oxidant levels 
(Trachootham et al., 2009) (Figure 51). All these cellular events may further increase ROS 
levels, resulting in additional DNA damage and genetic instability. Such a vicious cycle 
could eventually amplify oxidative stress and cause genomic instability and cancer 
development. 
 
Figure 51: The vicious cycle of ROS stress in cancer (Trachootham et al., 2009). 
In the present study the results of section 3.3 suggest that oxidative stress may be 
mediating cell death in both the glioma cell lines when treated with compound 209. 
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Carcinogenesis follows a multistep course involving both mutation and greater cell 
proliferation whilst oxidative stress occurs due to excessive production of reactive oxygen 
species through either endogenous or exogenous reactions. In the context of carcinogenesis, 
the unregulated or extended production of cellular oxidants has been linked to mutation 
which is induced by oxidant-induced DNA damage as well as modification of gene 
expression (Klaunig and Kamendulis, 2004). In particular, signal transduction pathways, 
including activator protein 1 (AP-1) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), are known to be activated by reactive oxygen species, and they 
lead to the transcription of genes involved in cell growth regulatory pathways (Klaunig and 
Kamendulis, 2004). Since the excessive production of ROS is capable of inducing many 
reactions and mutations in cancer cells, in such a short span of time, it was considered as 
being a potential mechanism via which the potent indole (compound 209), discovered from 
the current study, mediated cell death. 
The relevance of the inclusion of such a study here is corroborated by research 
which has shown that cancer cells produce higher levels of ROS than normal cells and 
oxidative damage to cellular DNA can lead to mutations and may, therefore contribute to 
rapid cancer progression (Pelicano et al., 2004; Schumacker, 2006; Waris and Ahsan, 
2006). It has also been shown that rat and human glioma cells overexpress 2-Cys Prx II, a 
cytosolic peroxide and peroxynitrite-scavenging anti-oxidant enzyme, when compared with 
their normal cell counterparts, the astrocytes. Additionally, knocking down Prx II led to an 
increase in radio-sensitivity at clinically relevant doses as low as 1 Gy, and to an increased 
sensitivity to oxidative stress. These data suggest that overexpression of Prx II protects 
cancer cells from oxidative stress. As ROS production is increased in cancer cells, 
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overexpression of Prx II may provide additional protection against ROS while presenting it 
as a potential therapeutic target (Smith-Pearson et al., 2008). 
Recent studies have also found that chemo-resistance to temozolomide (TMZ), the 
blockbuster drug for the treatment of malignant glioma, is linked to tighter mitochondrial 
coupling and low ROS production, and this suggests a novel mitochondrial ROS-dependent 
mechanism underlying TMZ-chemo-resistance in glioma. Thus, alteration of mitochondrial 
functions and changes in redox status might constitute a novel strategy for sensitising 
glioma cells to therapeutic approaches (Oliva et al., 2011), suggesting that controlling ROS 
generation or its levels may hold a promising standard therapeutic strategy for various types 
of cancers and thus support the continued development of the best compounds found here, 
compound 209 (and 223a, if its acid-sensitivity can be controlled).  
In a related manner, recent studies have also shown that piperlongumine, a natural 
product constituent of the fruit of the Long pepper, a plant found in southern India and 
southeast Asia, induces ROS and apoptotic cell death in both cancer cells, and normal cells 
engineered to have a cancer genotype, irrespective of p53 status, but that it had little effect 
on primary normal cells (Raj et al., 2011). Substantial anti-tumour effects were observed in 
piperlongumine-treated mouse xenograft tumour models, with no apparent toxicity to 
normal mice, which further indicates and supports that ROS mediated cell death pathways 
hold a promising therapeutic strategy in the future, which in this case is its ability to induce 
apoptosis selectively in cells that have a cancer genotype (Raj et al., 2011). 
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3.7.5 Co-treatment of the cells with compound 209 and a ROS scavenger 
(ascorbic acid) 
Under oxidative stress, reactive oxygen species, including free radicals such as 
superoxide (O2.-), the hydroxyl radical (HO.) and hydrogen peroxide (H2O2), are generated 
at high levels, inducing cellular damage and cell death (Pelicano et al., 2004). Ascorbic 
acid is a naturally occurring organic compound with anti-oxidant properties and is a 
scavenger of hydroxyl radicals (Biswas et al., 2005; Ozyurek et al., 2008), whereby it 
reacts with reactive oxygen species, such as the hydroxyl radical formed from hydrogen 
peroxide, and neutralises it (Jansson et al., 2003). The main objective of these anti-oxidant 
molecules is to donate an electron to, or to gain an electron from, ROS in order to 
neutralize them. Therefore, based on this mechanism, ascorbic acid was chosen to validate 
the ROS production induced by compound 209 in the 1321N1 and U87MG cell lines.  
1321N1 and U87MG glioma cells were treated with compound 209 and an anti-
oxidant, ascorbic acid (500 µM), a common scavenger for hydroxyl radical reactive oxygen 
species (Hou et al., 2010), to detect whether oxidative stress decreases after the addition of 
the anti-oxidant. As before, the MTS assay (section 2.3.1) was used to check the cell 
viability of the 1321N1 and U87MG cell lines and the amount of viable cells was 
determined after treating the cells with compound 209 (500 µM) alone for 1 h, and the 
result of this experiment were consistent with those observed in section 3.2 and Figure 44 
and Figure 45, in that only 50-60 % of the cells were viable after treatment. However, upon 
co-treatment with the anti-oxidant (ascorbic acid, 500 µM) and compound 209 (500 µM) 
for 1 h, the cell viability increased to circa 90 % for both cell lines, Figure 52, suggesting 
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that the anti-oxidant was able to neutralise the effects of compound 209 almost completely, 
presumably because the indole is acting through a oxidative stress mechanism. 
 
 
 
 
 
 
 
 
 
 
Figure 52: 1321N1 (A) and U87MG (B) cells co-treated with compound 209 (500 µM) and ascorbic acid (500 
µM) for 1 h. Ascorbic acid was used as a scavenger for hydroxyl reactive oxygen species and the MTS assay 
was used to measure the cell viability. The data points are means of 4 repeats and the error bars represent 
±SD. 
The results were also confirmed by flow cytometry analysis where it was 
demonstrated that the level of fluorescence produced by the cells treated with compound 
209 alone was greater than the fluorescence produced by the cells treated with compound 
209 + ascorbic acid. This validated the hypothesis and it was confirmed that the addition of 
the anti-oxidant, ascorbic acid, reduced the anti-cancer potency of compound 209 by 
scavenging ROS. The 1321N1 cell line showed a decrease in the percentage of ROS 
positive cells from 88.53 % when treated with compound 209 alone to 38.6 % with 
compound 209 + ascorbic acid, whilst the U87MG cell line showed a decrease from 79.33 
%  when treated with compound 209 alone to 55.96 % with compound 209 + ascorbic acid 
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for 1 h (table 11). The percentage of ROS positive cells was calculated by comparing them 
with the control cells, thus eliminating the basal levels of ROS which are present in each of 
the cells. 
Table 11: The percentage of ROS positive cells when treated with compound 209 and compound 209 + 
ascorbic acid for 1 h. Carboxy-H2DCFDA staining intensity was quantified by flow cytometry and the 
following values are the means of 3 repeats. (t-test, P < 0.05 for compound 209, SD = Standard deviation). 
                        Compounds 
Cell lines 
209 209 + ascorbic acid 
1321N1 88.53 ± 3.90 SD 38.60   ± 3.3 SD 
U87MG 79.33 ± 6.50 SD 55.96 ±3.56 SD 
 
A recent study on human and mouse melanoma cells showed that doxycycline 
induces intra-cellular ROS production, apoptosis signal-regulated kinase 1 (ASK1), JNK 
and p38 mitogen-activated protein kinase (MAPK) activation at an early stage of treatment 
and induces mitochondrial cytochrome c release into the cytosol (Shieh et al., 2010). In that 
study, the same ROS scavenger to that used here, ascorbic acid, reduced doxycycline-
induced JNK activation, caspase cleavage and melanoma cell death. This result is an 
indication that intra-cellular ROS generation is responsible for doxycycline-induced JNK 
activation and melanoma cell apoptosis and that ascorbic acid scavenges ROS (Shieh et al., 
2010). Therefore, this supports the results here in that the addition of ascorbic acid to the 
cells treated with compound 209 are showing reduced amounts of ROS production, further 
confirming that compound 209 is working through a mechanism involving ROS. 
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3.8 Detection of Autophagy 
Further evidence for the ROS-induced mechanism of action of these compounds 
came about following a recent study which showed that oxidative stress can induce 
autophagy ahead of apoptosis in U251 glioma cells (Kong et al., 2011). The results of the 
study indicate that autophagic vacuoles and the expression of the autophagic protein, Beclin 
1, increase at 6 h, but that the cell apoptotic ratio and cytosolic cytochrome c protein do not, 
but only increase after 12 h (Kong et al., 2011). Based on this result, in these glioma cell 
lines, there appears to be a time dependent relationship of apoptosis with autophagy, 
indicating that compound 209 used in this study, which induces ROS, is not causing 
apoptosis mediated cell death (at least at first) but may be causing autophagy mediated cell 
death initially. 
Autophagy is a highly conserved process which is characterised by the sequestration 
of bulk cytoplasmic proteins and organelles in autophagic vesicles, and subsequent delivery 
to and degradation by the lysosomal system. It was originally considered as a process for 
protein recycling and is termed as Type II programmed cell death (Klionsky, 2007). 
Autophagy is responsible for non-apoptotic cell death, and plays a crucial role in regulating 
cellular functions (Park et al., 2011). Oxidative stress has been shown to induce autophagy 
under certain conditions, such as ischemia and reperfusion (Matsui et al., 2007), and cell 
death by autophagy in tumour cell lines treated with chemotherapeutic agents has been 
proposed (Levine and Yuan, 2005; Bursch et al., 2000).  
As discussed earlier, a recent study by Park et al. (2011) on U87MG cells, observed 
that ROS levels increased within 30 min followed by autophagic cell death following 
treatment with β-lapachone. Similar to Park’s work it was also observed in the current 
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study that glioma cells treated with compound 209 had elevated amount of ROS production 
within 1 h (section 3.7.3.1). With this result in mind, and trying to replicate the protocol of 
Park et al (2011), it was decided to determine if the cells were in the stages of an 
autophagic process, which may have been mediated by the ROS generated and observed in 
section 3.3. 
Autophagy is characterised by acidic vesicular organelle formation 
(autophagosomes) (Prabhu et al., 2013a) and research has shown that vinblastine, an anti-
microtubule drug (section 1.2.2.2.5), triggers autophagosome formation very quickly (30 
min) in primary rat hepatocytes (Kochl et al., 2006). Here too, the MTS assay results 
reported non-viable cells within 2 h upon treatment with compound 209, leading to the 
hypothesis that such quick cell death might be related to autophagy. 
The characteristic AVO formation of autophagy can be detected by staining the 
cells with acridine orange, and so to try and prove the formations of AVOs in 1321N1 and 
U87MG cell lines after treatment with compound 209, and that cell death did involve an 
autophagic process, the cells were treated with compound 209 for 1 h followed by 
incubation with acridine orange as per the supplied protocol. Acridine orange moves freely 
across biological membranes and accumulates in acidic compartments, where it can be 
observed as bright red fluorescence (Paglin et al., 2001). The intensity of the red 
fluorescence is proportional to the degree of acidity. Therefore, the volume of the cellular 
acidic compartment can be quantified (Traganos and Darzynkiewicz, 1994). In view of the 
finding that AVOs accumulate in cells undergoing autophagy (Zou et al., 2011; Kanzawa et 
al., 2005), acridine orange was used to characterise AVO formation and detect possibly 
autophagy, in the 1321N1 and U87MG glioma cell lines.  
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According to the trypan blue exclusion test results (section 3.1.2), membrane lysis 
occurs after 75 min upon treatment with compound 209, and therefore it was crucial that 
the cells were not treated with this compound for more than 60 min, since membrane lysis 
would have hampered acridine orange staining. Membrane lysis would have caused this 
stain to leak out and possibly generate false negative results.  
Upon carrying out such experiments, the cells treated with compound 209 showed a 
greater amount of red fluorescence compared to the control untreated cells, as indicated by 
the shift in the control peak. This result suggests that compound 209 induces AVO 
formation in the 1321N1 (Figure 53) and U87MG (Figure 54) cell lines (table 12), 
indicating that the cells were in a stage of an autophagic process, and that this may have 
been mediated by ROS formation (oxidative stress). 
Further evidence for this proposal consisted of using an autophagy inhibitor—3-
methyladenine (Sigma-Aldrich, UK) (5 mM)—on both the glioma cell lines (1321N1 and 
U87MG), to determine if autophagy was indeed inhibited after treatment with compound 
209 (McFarland et al., 2012). In this event, the results indicated that the peak did indeed 
shift back towards the control cell level, on both the cell lines (Figure 53C and Figure 54C), 
indicating that autophagy was being inhibited in the samples which were treated with 3- 
methyladenine prior to treatment with compound 209. More specifically, compound 209 
showed 15.66 % and 16.33 % of acridine orange positive cells  on the 1321N1 and U87MG 
cell lines respectively whilst this reduced to 6.66 % (1321N1) and 2.13 % (U87MG) when 
pretreated with 3-methyladenine on both the glioma cell lines (table 12).  
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Table 12: The percentage of acridine orange positive cells when treated with compound 209 and 3- 
methyladenine for 1 h. Acridine orange staining intensity was quantified by flow cytometry and the following 
values are the means of 3 repeats. (t-test, P < 0.05 for compound 209, SD = Standard deviation). 
                    Compounds 
Cell lines 
209 209 + 3-methyladenine 
1321N1 15.66 ±3.78 SD 6.66 ±0.61 SD 
U87MG 16.33 ± 3.51 SD 2.13 ±0.40 SD 
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Figure 53: Acidic vesicular organelle (AVO) formation in 1321N1 cells. 
(A) 1321N1 control cells + acridine orange (3 µM) (B) 1321N1 cells treated with compound 209 (500 µM) 
for 1 h + acridine orange (3 µM) (C) 1321N1 cells treated with compound 209 (500 µM) + 3-methyladenine 
(5 mM) for 1 h. Acridine orange staining intensity was quantified by flow cytometry. Representative data 
from one of three experiments yielding similar results is shown. 
B 
 
A 
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Figure 54: Acidic vesicular organelle (AVO) formation in U87MG cells. 
(A) U87MG control cells + acridine orange (3 µM) (B) U87MG cells treated with compound 209 (500 µM) 
for 1 h + acridine orange (3 µM) (C) U87MG cells treated with compound 209 (500 µM) + 3-methyladenine 
(5 mM) for 1 h. Acridine orange staining intensity was quantified by flow cytometry. Representative data 
from one of three experiments yielding similar results is shown. 
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The results shown here are supported by the research of others which have shown 
that cell death can occur through an autophagic process in various cancers, including 
malignant gliomas, ovarian carcinomas and mammary carcinomas (Kanzawa et al., 2005; 
Opipari et al., 2004; Bursch et al., 1996). It has also been shown that using hydrogen 
peroxide (H2O2) and 2-methoxyestradiol (2-ME) to induce oxidative stress, causes 
autophagy-induced cell death in the transformed cell line HEK293, and the  cancer cell 
lines U87MG and HeLa (Chen et al., 2008). Resveratrol, which is structurally similar to 
compound 209 (Figure 30 and Figure 33), has also been shown to induce autophagy in 
human U251 glioma cells (Li et al., 2009). 
Research has also shown that radiation or chemotherapeutic agents such as arsenic 
trioxide or tamoxifen induce autophagy, but not apoptosis, in several cancers, including: the 
malignant glioma cell lines U373 and U87MG (Bursch et al., 1996; Yao et al., 2003; 
Kanzawa et al., 2003; Paglin and Yahalom, 2006). Previous studies have also shown that 
apoptosis is mediated by caspases, yet caspase inhibitors do not halt arsenic trioxide 
induced cell death (Kanzawa et al., 2003), as such, the autophagy-induced cell death 
observed in the above described cell lines, did not exhibit any of the characteristic apoptotic 
features, such as caspase activation and DNA fragmentation (Voss et al., 2010). Since the 
onset of cell death was quick (1.5 h) in the current study, it can be speculated that apoptosis 
may not be the main mechanism of cell death, since the above findings suggest that 
compound 209 works via a ROS mediated mechanism, which leads to autophagic cell 
death, in 1321N1 and U87MG cell lines. However, as has been observed by others, it is not 
being ruled out that apoptosis may be involved at a later stage, after autophagy has taken 
place (Kong et al., 2011). 
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A previous study has shown that arsenic trioxide induces autophagic cell death in 
U373-MG glioma cells when exposed for 24 h, by up regulating the mitochondrial cell 
death protein BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) 
(Kanzawa et al., 2005). Staining of U373-MG glioma cells with acridine orange showed the 
accumulation of AVO in the cytoplasm of cells exposed to arsenic trioxide (Kanzawa et al., 
2005), suggestive of autophagy induced cell death (Zou et al., 2011). Moreover, malignant 
glioma cells U373-MG when treated with temozolomide for 72 h, are also known to be in 
an autophagic process (Kanzawa et al., 2004). Collectively, all these findings indicate that 
autophagic cell death pathways play an important role in inducing cell death in cancer cells. 
Another previous study has also shown that the amount of oxidative stress-induced 
cell death may not be completely blocked by inhibiting either apoptosis or autophagy (Chen 
et al., 2008). This is an indication that there is a third type of cell death pathway; necrotic 
cell death. This form of cell death is passive and causes cellular contents to be released into 
the extracellular space which is indicated by cell lysis (Chen et al., 2008). Reports have 
shown that when apoptotic or autophagic cell death was blocked, necrotic cell death was 
observed (Degenhardt et al., 2006). Furthermore, oxidative stress has been shown to trigger 
a lysosomal-dependent necrotic cell death (Brunk et al., 1997). Therefore, it can be 
assumed that cells under oxidative stress could undergo cell death through multiple 
pathways including necrosis. In this current study, membrane lysis was observed within 1.5 
h of treatment with compound 209 at high concentrations (> 750 µM) which may suggest 
that the cells are undergoing necrosis when treated with high concentrations of this indole 
(compound 209) and hence concentration/time studies are important. From the above 
results, it may be speculated that the cells may be in a stage of an autophagic process when 
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treated with compound 209 for 1 h at 500 µM. Following an increase in the concentration 
of compound 209 to 750 µM, the cells may move to a necrotic stage, since membrane lysis 
was observed, as indicated by the trypan blue exclusion test (section 3.1.2), at this 
concentration. This suggests that the concentrations of these indoles may play an important 
role in deciding the type of cell death pathway to be followed, as has been observed for 
other phenolic compounds which are either anti-oxidant (at low concentrations) or pro-
oxidants (at high concentrations) (Iwasaki et al., 2011; Fujisawa et al., 2005). The pro-
oxidant or anti-oxidant activity of phenolic compounds is also dependent on factors such as 
their metal-reducing potential, pH, chelating behaviour and solubility characteristics 
(Fujisawa et al., 2005).  
It is known that the pro-oxidant activities of phenolic compounds are catalysed by 
numerous peroxidases, such as plasma myeloperoxidase and cytochrome P-450, which 
results in the production of pro-oxidant phenoxyl radicals (Fujisawa et al., 2005), and a 
recent study showed that there are high levels of cytochrome P450 (CYP) expression found 
in U87MG cells (Stiborova et al., 2011). In the current study, it was shown that the 
phenolic indole, compound 209, generates ROS in both the U87MG and 1321N1 cell lines, 
and that the elevated CYP expression known to occur in glioma cell lines might be 
responsible for compound 209’s increased pro-oxidant activity seen here.  
Research has shown that the 2-electron reductase, NAD(P)H:quinone 
oxidoreductase (NQO1) is overexpressed in many solid tumours (Awadallah et al., 2008) 
and NQO1 is a priority target of glioblastoma chemotherapy (Okamura et al., 2000). As 
shown herein, the most stable, potent compound used in this study (compound 209) caused 
the cells to be in a stage of an autophagic process within 2 h. Since the time required for the 
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cells to induce autophagy was so quick, it may indicate that the mechanism of action of 
compound 209 may be similar to that of β–lapachone, since β–lapachone induces NQO1-
dependent cell death within 2–4 h in NQO1-expressing lung and prostate cancer cells (Park 
et al., 2011). The U87MG cell line used in this study also expresses the NQO1 gene (Park 
et al., 2011). The NAD(P)H:quinone acceptor oxidoreductase (NQO) gene family in the 
human genome consists of two genes (NQO1 and NQO2). These two genes encode 
cytosolic flavoenzymes that catalyse the beneficial two-electron reduction of quinones to 
hydroquinones, a reaction which prevents the unwanted one-electron reduction of quinones 
by other quinone reductases. This reaction is unwanted because it results in the formation 
of highly reactive oxygen species which leads to cell damage (Vasiliou et al., 2006). 
Compound 209, used in this study, has a phenolic –OH group which is thought to be an 
important component for its activity (section 3.3.2) and this –OH group may be 
participating in a similar redox processes resulting in an unwanted one-electron system and 
generating reactive oxygen species which could then lead to autophagic cell death. Both the 
mammalian NQO1 and NQO2 genes are up-regulated as a part of the oxidative stress 
response and are overexpressed in various types of tumours (Vasiliou et al., 2006). 
Therefore, considering previous studies and the results obtained from this current study 
together, it may indicate that compound 209 induces ROS formation within 1 h, which in 
turn leads the glioma cells to be in an autophagic process, as indicated by AVO formation 
and the effects of using an autophagy inhibitor, 3-methyladenine. The fact that the cells 
may undergo cell death via multiple pathways (Chen et al., 2008), which may be triggered 
any time during the course of cell cycle, means that testing the cell lines for apoptosis 
induced cell death at a later time point (48 h) would be a topic of future study. 
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3.9 Effects of compound 209 on a primary cell culture 
The activity of compound 209 on the glioma cell lines has been reliably reproduced 
during these studies, and its mechanism of action appears to include ROS linked to an 
autophagic process. However, the cell lines used are immortalised and do not completely 
represent a patient’s brain tumour in vivo. As such, a primary cell line was obtained from a 
patient biopsy from Royal Preston Hospital, and screened against compound 209 to see if 
the activity observed on the established cell lines could be mirrored on cells more 
reminiscent of an actual tumour.  
As such, a dose response curve of compound 209 on the primary cell line, IN859, 
was plotted using the MTS cell proliferation assay, wherein the cells were exposed to 
different concentrations of the compound for 2 h. As shown in Figure 55, the IC50 value of 
compound 209 was found to be 400 ±4 µM on this primary cell line, an activity which is 
almost double that seen in the established cell lines (section 3.2).  
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Figure 55: Compound 209 tested on the IN859 primary cell line for 2 h. The data points are means of 4 
repeats. 
Such a primary cell line was used to substantiate and support the results obtained 
using the established cell lines, because a primary cell line would mimic in vivo conditions 
more appropriately and closely as compared to established cell lines. There is a greater 
chance of mutation in the established cell lines because the process of in vitro 
transformation of a primary cell line to a continuous, established cell line leads to genetic 
variations involving deletion or mutation in the p53 gene. This gene plays a major role in 
cell cycle arrest if DNA were to become mutated and therefore it is not surprising to find 
genetic instability perpetuated in continuous established cell lines (Freshney, 2010). 
Therefore, for the compounds studied herein, and any future analogues prepared, it is 
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significant that activity is also seen on cells which more closely represent human brain 
tumours if future therapies for glioma are to be developed successfully. 
3.10 Summary of the proposed ROS-induced mechanisms 
of cell death 
As a possible aid for determining the absolute mechanism of cell death induced by 
ROS, all the above work and literature references have been summarised by building a 
flowchart model (Figure 56) which demonstrates how ROS-mediated cell death is caused 
by different types of compound, over differing time points and cell types. The various 
compounds in this flowchart are categorised under five classes on the basis of the time 
required to trigger cell death, and also by the type of programmed cell death mechanisms 
(apoptosis, autophagy and necrosis) taking place. For example, looking at the flowchart, β-
lapachone is classified as a class IV compound since it leads to autophagic cell death within 
24 h, while compound 209 is classified as a class I compound, since it causes the cells to be 
in a stage of an autophagic process within 2 h. All other compounds are classified 
according to the same principle. 
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Figure 56: Flowchart model depicting ROS mediated cell death mechanism. 
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3.11 Cn-AMP2, a host defence peptide (HDP) against the 
glioma cell lines, 1321N1 and U87MG. 
 Globally, cancer is now one of the leading causes of death, which claimed lives at an 
annual rate of over 12.7 million in 2008 and is predicted to rise to over 20 million by 2030 
(Bray et al., 2012), creating an urgent need for novel approaches to anticancer therapies 
(Martin Sabroso and Torres-Suarez, 2014; Saraswathy and Gong, 2013; Urruticoechea et 
al., 2010). In response, there has been a move to develop anticancer strategies that are 
based on compounds from natural sources (Cragg et al., 2009; Balderas-Renteria et al., 
2012; Cragg and Newman, 2013; Newman and Cragg, 2012), including host defence 
peptides (HDPs) (Harris et al., 2013a; Dennison et al., 2006a; Gaspar et al., 2013). 
However, presently, the only major candidate in this class of peptides with promise for 
medical use is the neutraceutical protein, lactoferrin, which has been patented as an 
anticancer agent and in clinical trials has been shown to reduce the risk of colon 
carcinogenesis (Tsuda et al., 2010). Given this lack of therapeutically useful HDPs and the 
fact that most tested in this capacity are cationic, the ability of the anionic plant HDP, Cn-
AMP2, to serve in this capacity has been investigated. This work constitutes a separate 
short, parallel study, which extends and complements that described above, in that, it 
considers the anti-cancer potential of naturally occurring compounds with molecular 
weights higher than indoles but lower than monoclonal antibodies (mABs). This 
collaborative project was also undertaken to optimise resource economy, in that, the cell 
cultures and other systems needed to test the peptide’s anti-cancer activity were already in 
place.  
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The ability of Cn-AMP2, to kill the glioma cell lines, 1321N1 and U87MG was 
investigated and these data were plotted as dose response curves (Figure 59) and used to 
estimate the IC50 values of the peptide for each cell line. The effect of 72 h incubation with 
Cn-AMP2 on the morphology of these cell lines was examined using an inverted 
microscope since 48 h incubation did not show any effect. When micrographs of cells from 
1321N1 and U87MG cultures, which were treated with the peptide at final concentrations 
of both 1 mM and 2 mM, were compared to those which acted as controls, cell numbers 
were seen to be significantly less in the treated cells. These micrographs also showed that 
cells treated with Cn-AMP2 exhibited no significant differences in morphology to that of 
control cells; no evidence of cell-death was observed, as indicated by a round morphology 
and detachment from the monolayer; and no sign of cell-lysis, as witnessed by membrane 
fragmentation. Representative micrographs of these peptide-treated cells are shown in 
Figure 57. 
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Figure 57: The morphology of 1321N1 cell line after incubation with Cn-AMP2.  
Inverted microscope acquisitions of the 1321N1 glioma cell line at 10X magnification when cultured in 
DMEM with an FBS concentration of 2.5 % (v/v) and incubated for 72 h either in the absence (A) or presence 
of Cn-AMP2 at a final concentration of 1 mM (B) or 2 mM (C). It can be seen that there are no significant 
differences between the morphology in the case of cultures treated with peptide (B), no observable evidence 
of dead cells, as indicated by a round morphology and detachment from the monolayer, or lysed cells, as 
witnessed by membrane fragmentation or the release of cellular debris, was seen. 
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The sequences of the HDPs studied here were represented as two-dimensional axial 
projections. It was found that Cn-AMP2 possessed the potential to form a weakly 
amphiphilic α-helix with no strongly defined segregation of hydrophobic and hydrophilic 
amino acid residues (Figure 58). It can be seen that the longest stretch of uninterrupted 
hydrophobic residues found in this α-helix is the arc formed by the amino acid residues, 
YMF whilst the peptide’s sole negatively charged residue is sandwiched between two 
hydrophobic V residues (Figure 58A). This contrasts to the α-helix formed by the chosen 
reference peptide, temporin 1-Ja, which possesses the potential to form a strongly 
amphiphilic α-helix. It can be seen that this α-helix exhibits a clear segregation of residues 
to form a short anionic, hydrophilic arc formed by the residues DNPN, which is opposed by 
a long a hydrophobic arc comprising the residues, LLILVLLL (Figure 58B).  
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Figure 58: Peptides represented as two-dimensional axial projections.  
The sequences of Cn-AMP2 (A) and temporin-1-Ja (B) represented as two-dimensional axial projections. It 
was found that Cn-AMP2 possessed the potential to form a weakly amphiphilic α-helix with no strongly 
defined segregation of hydrophobic and hydrophilic amino acid residues. In contrast, temporin 1-Ja possessed 
the potential to form a strongly amphiphilic α-helix as indicated by the clear segregation of residues to form 
hydrophobic and hydrophilic arcs. The single letter code is used to represent amino acid residues, 
hydrophobic residues are coloured beige, anionic residues are coloured purple, polar residues are coloured 
blue and neutral residues are coloured red. 
A 
B 
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It was found by the MTS assay that Cn-AMP2 exhibited no apparent effect on the 
1321N1 and U87MG cell lines when incubated in DMEM medium containing 10 % (v/v) 
FBS. However, when FBS levels in DMEM were decreased to 2.5 % (v/v), the presence of 
the peptide led to large reductions in the viability of cell lines when compared to controls, 
implying that FBS has an effect on the action of Cn-AMP2. Similar findings have been 
reported by studies on the anti-cancer activity of other host defence peptides (Zhang et al., 
2010) and it has previously been suggested that binding of the host defence peptide (HDP) 
to serum proteins, such as low-density lipoprotein, may contribute to this inhibitory effect 
on the anti-cancer activity of these peptides (Peck-Miller et al., 1993). 
It was found that as the concentration of Cn-AMP2 was increased up to 2 mM in the 
presence of either the 1321N1 (IC50 = 1.25 mM) or U87MG (IC50 = 1.85 mM) cell lines, the 
number of viable cells decreased by up to 70 % compared to controls. It can be seen that, as 
compared to controls, the presence of the peptide at final concentrations of 1 mM and 2 
mM led to a reduction in the viability of both the 1321N1 and U87MG cell lines that varied 
between 25 % and 70 % (Figure 59). 
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Figure 59: Dose response curves using the MTS assay for the action of Cn-AMP2 against the 1321N1 and 
U87MG glioma cell lines when cultured in DMEM with an FBS concentration of 2.5 % (v/v). The data points 
are means of 4 repeats and the error bars represent ±SD. 
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 Comparable levels of another plant HDP, Cr-ACP1 from Cycas revoluta, were 
recently found to be required for effective activity against the cancer cell lines Hep2A, 
which is a human epidermoid cancer, and HCT15, which is a colon carcinoma (Mandal et 
al., 2012). Microscopic examination of these cancer cells peptide-treated showed that these 
decreases in cell viability did not appear to be accompanied by cell-death or cell-lysis. In 
combination, these data suggest that Cn-AMP2 may be active against the 1321N1 and 
U87MG cell lines by entering target cancer cells and inhibiting their ability to proliferate 
using an, as yet, undetermined mechanism. It is well established that a number of HDPs 
exert their anticancer activity by non-membranolytic mechanisms and enter the cancer cell 
to attack intracellular targets such as DNA. To exert this inhibitory action it may require 
Cn-AMP2 to translocate across the cancer cell membrane and it has previously been 
suggested that the peptide may interact with membranes by the adoption of an amphiphilic 
α-helical structure (Mandal et al., 2009). However, theoretical analysis here showed that 
Cn-AMP2 has the potential to form only a weakly amphiphilic α-helix as it does not 
possess any strongly defined segregation of hydrophobic and hydrophilic amino acid 
residues. Moreover, recent biophysical studies showed that the peptide exhibited a linear 
extended structure in the presence of lipid systems mimetic of cancer cell membranes 
(Prabhu, 2011) and it seems possible that this could represent the form of the peptide which 
facilitates its passage across the cancer cell membrane. Visual examination of the primary 
structure of Cn-AMP2 shows that the C-terminal eight residues of the peptide 
(YFVFSVGM) form a strongly hydrophobic region, which is flanked by a short charged 
segment (TES). This residue arrangement is an example of primary amphiphilicity that has 
been reported for other anti-cancer peptides such as indolicidin and is known to mediate the 
ability of these peptides to traverse membranes. By analogy to indolicidin, the anionic 
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segment of Cn-AMP2 (TES) would interact with positively charged moieties in the cancer 
cell membrane such as the choline group of phosphatidylcholine. Concomitantly, the 
hydrophobic region of the peptide (YFVFSVGM) would penetrate the membrane core 
region, thereby driving translocation of the peptide across the cancer cell membrane to 
attack intracellular targets. It is also possible that the strongly hydrophobic C-terminal 
region of the peptide may bind serum components, contributing to the apparent lack of anti-
cancer activity shown by Cn-AMP2 in media containing high levels of serum. 
In summary, this study has shown that Cn-AMP2 has activity against several human 
gliomas, expanding the small repertoire of anionic HDPs known to possess anticancer 
activity (Harris et al., 2011; Harris et al., 2009a). The action of Cn-AMP2 against these 
cancer cells appears to involve anti-proliferative mechanisms, which result from the ability 
of the peptide to translocate cancer cell membranes through a hydrophobicity-driven 
mechanism. Use of this mechanism would seem to reflect the fact that Cn-AMP2 is devoid 
of cationic residues and therefore lacks the capacity to engage in the electrostatically-driven 
mechanisms of cancer cell targeting utilised by most HDPs (Harris et al., 2013a). However, 
this lack of cationic residues could also give Cn-AMP2 an advantage over cationic HDPs 
with anticancer action whose possession of lysine and arginine residues makes them highly 
susceptible to degradation by human proteases (Cho and Kim, 2010; Riedl et al., 2011). 
Clearly, the levels of Cn-AMP2 shown here to be necessary for anticancer activity are 
prohibitive for the therapeutic application of the peptide. However, this would appear to be 
one of the first demonstrations that an anionic HDP can exert an anti-cancer effect and 
given the urgent problems due to the increasing global prevalence of cancer, it is suggested 
that Cn-AMP2 may represent a template for the development of novel HDPs with clinically 
useful, anti-cancer activity. 
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4.Conclusion and future work 
4.1 General conclusions 
Reactive oxygen species (ROS) induce various types of cell death, depending on the 
cell type, concentration, and the duration of exposure (Trachootham et al., 2009). In the 
current study, it was attempted to evaluate whether the novel indoles tested in the current 
study show any anti-cancer activity and if any, then to find the active compound’s 
mechanism of action. Based on the present findings, it may be concluded that compound 
209 induced rapid cell death (< 2 h) in the above mentioned cell lines via the generation of 
ROS which then may have mediated the cells to be in a stage of autophagic process leading 
to cell death. The most stable and potent compound (209) was found to be active on the 
non-cancerous SVGp12 cell line as well as the primary short-term culture designated as 
IN859. The IC50 value of compound 209 was relatively low on the primary cell line as 
compared to commercial cell lines suggesting that it may act as a potential anti-cancer drug 
when optimised fully in the future.  
The findings from this current study are consistent with previous reports showing an 
association between ROS generation and autophagic cell death (Chen et al., 2008; Park et 
al., 2011). Since oxidative stress can induce different types of cell death mechanism 
including autophagy in various cell types, this may lead to different strategies in developing 
therapeutic drugs. One of the strategies being, optimising these drugs by analysing their 
structure-activity-relationships in such a way that they could selectively target cancer cells 
and undergo autophagy induced cell death independent of apoptosis. Such an approach may 
reveal a potential mechanism of targeted cytotoxic activity.  
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In addition to indoles, the anti-cancer potential of the HDP, Cn-AMP2, was 
investigated and the peptide was found to have an anti-proliferative effect against the 
glioma cell lines tested but only at high concentrations. It would therefore seem that the 
peptide might not be of therapeutic importance in its current form due to the high 
concentrations required to show an effect on the cancer cell lines. However, this would 
appear to be the first demonstration that an anionic HDP can exert an anti-cancer effect and 
it is possible that Cn-AMP2 may serve as a template for the development of future agents 
with activity against cancer cells.  
In conclusion, it has been demonstrated that the ability of certain substituted 
privileged indoles may have a rapid, deleterious effect on the viability of primary cell line 
(IN859) and two glioma cell lines (1321N1 and U87MG) and that the mechanism of action 
of these indoles to cause cell death may be via the generation of ROS, which in turn leads 
the glioma cells to be in a stage of an autophagic process, as indicated by AVO formation 
and by using an autophagy inhibitor, 3-MA. Besides, the HDP, Cn-AMP2 was found to 
have an anti-proliferative effect against both the glioma cell lines (1321N1 and U87MG) 
tested but only at higher concentrations (> 1mM). 
4.2 Scope for future studies 
There appears to be huge scope for future research on these privileged indoles as 
they are able to induce rapid (~ 2 h) cell death in high-grade glioma cell lines and in a 
primary short-term culture, via the generation of ROS leading to autophagy-induced cell 
death. There are various avenues which could be studied further to tap the full potential of 
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these 2-aryl indoles. Some of the future studies which can be performed, subject to the 
availability of adequate funding and resources, are listed below. 
Three dimensional (3D) cell culture techniques might be suitable in the immediate 
future for testing the potent compound (209) so that its mechanism of action could be 
studied in more detail. Use of 3D culturing techniques may help mimic the mode of action 
of the potent compound (209) in vivo and will also help save money on expensive animal 
testing. However, 3D cell culture remains open to major improvements at this point in time 
but can prove very useful once developed properly, and the results using it obtained 
become reproducible.  
Future extensive research will be required to optimise the activity of these indoles. 
The major criterion to be taken into consideration for future work here is to analyse the 
structure-activity-relationships further, so that the indoles could be optimised for anti-
cancer activity selectively. This study suggested that possessing an –OH group alone is not 
enough for the anti-cancer activity and that the entire structure (and possible the indole 
nucleus itself), as a whole, is required. Therefore, future work should be focused on 
synthesising more derivatives and analogues based on this entire structure after which 3D 
cell culture studies could be performed on the best compounds obtained. 
Another important aspect to look into could be that the indoles can be optimised in 
such a way that low concentrations (< 100 µM) can prove effective because in the current 
study the concentrations used are relatively high when compared to the commercial drugs 
currently used to treat cancer. The potent compound (209) found in this study should also 
be tested on other types of cancer cell lines and primary cells because it is highly possible 
that these indoles could be specific in their modes of action such that they might have 
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differing activities on different cell lines. Furthermore, the indoles, found to be inactive in 
this study, should not be ignored and must be tested on other types of cancer cell lines and 
primary cells, as some of these indoles may be specific to certain types of cancers. These 
above factors may lead to new strategies for the development of therapeutic drugs that will 
selectively target specific types of cancers and therefore further testing of these compounds 
is essential in the future. These novel indoles can also be screened in the future with 
electron paramagnetic resonance (EPR) spectroscopy to check for unpaired electrons as 
these unpaired electrons may indicate if the compound has the potential to cause ROS 
mediated cell death in cancer cells. EPR spectroscopy is a technique for studying chemical 
species that have one or more unpaired electrons, such as organic and inorganic free 
radicals or inorganic complexes possessing a transition metal ion. Therefore, if compound 
209 is able to form a free radical as part of its ROS-forming behaviour, then this would be 
detected using EPR, thus confirming part of its mechanism of action. 
Molecular techniques such as qPCR and western blotting could also open another 
avenue as they can be used in future studies to find the molecular targets which are being 
targeted by these novel compounds. Western blotting will help in detecting which proteins 
are being over expressed in the cancer cells whilst qPCR could be used to study the specific 
autophagy related genes that may be up-regulated after treatment with these novel indoles. 
This will give a deeper insight in the workings of cell death mechanisms induced by these 
indoles. 
Currently, two main approaches have been used to develop new autophagy 
regulators (inhibitors or activators). The first approach is to screen small molecules 
targeting autophagy (Farkas et al., 2009; Zhang et al., 2007) and the second one is to be 
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able to design and improve autophagy regulators by studying the structural information of 
the Atg proteins (Miller et al., 2010). Further characterisation of the known 35 ATG genes 
(Kanki and Klionsky, 2010; Nazarko et al., 2011) and the discovery of additional genes 
involved in autophagy regulation will help to understand the autophagy induced cell death 
in depth. Recently, additional autophagy regulators have been discovered through such a 
screening approach (Balgi et al., 2009; Choi et al., 2010). For example, drugs already 
approved for human use, such as perhexiline, niclosamide and amiodarone can reversibly 
inhibit mTORC1 and stimulate autophagy (Balgi et al., 2009). The mammalian target of 
rapamycin (mTOR) is a protein which in humans is a serine/threonine protein kinase that 
regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and 
transcription (Hay and Sonenberg, 2004). Additional studies using these and various 
different approaches will be beneficial to understand the regulatory network of autophagy 
and in making the therapeutic modulation of autophagy a reality in the near future. 
In view of the peptide looked in the current study, the sequence of the HDP, Cn-
AMP2 can be used as a template for future research by performing permutations and 
combinations within these amino acid sequences as this may prove helpful in designing a 
new class of peptide. These peptides, including Cn-AMP2, should be then tested on 
different cancerous cell lines to determine if they prove more potent on those compared to 
the 1321N1 and U87MG cell lines tested in the current study.  
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5.Appendices 
5.1 Appendix I 
Synthesis and characterisation of indoles 
Commercially available reagents were used as received without purification. Analytical 
thin layer chromatography (TLC) was performed with plastic-backed TLC plates coated 
with silica G/UV254, in a variety of solvents. The plates were visualised by UV light (254 
nm). Flash column chromatography was conducted with Davisil silica 60Å (40-63 μm) 
under bellows pressure. Low resolution mass spectra were recorded on a Thermo Finnigan 
LCQ Advantage MAX using chemical ionisation (CI). 1H and 13C NMR spectra were 
recorded on a Bruker Avance DPX 250 (250 MHz) or a Bruker 400 (400 MHz) 
spectrometer. All chemical shifts (δ) are quoted in parts per million (ppm) relative to a 
calibration reference of the residual protic solvent; CHCl3 (δH 7.26, s) or DMSO (δH 2.53, 
m) was used as the internal standard in 1H NMR spectra, and 13C NMR shifts were 
referenced using CDCl3 (δC 77.0, t) or DMSO (δC 40.5, sept) with broad band decoupling. 
2-(2’-Methoxyphenyl)-1H-indole, 223 
2’-Methoxyacetophenone (1.38 mL, 10 mmol) was mixed with phenylhydrazine (0.99 mL, 
10 mmol) in ethanol (5 mL) and 4 drops of glacial acetic acid added. The pale yellow 
solution was heated to 80 °C with stirring for 1 hour which produced a red/brown solution. 
The solvent was evaporated to yield the phenylhydrazone intermediate as red/brown oil. To 
this oil was added polyphosphoric acid (20 g) and the reaction heated to 120 °C with 
stirring for 2 hours. After completion of the reaction (TLC) the reaction mixture was 
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poured onto crushed ice, followed by the addition of NaOH until a neutral pH was reached. 
The product was extracted with DCM (3 × 50 mL) and the combined extracts washed with 
water (50 mL), brine (50 mL), dried (MgSO4), filtered and the solvent evaporated. The 
product was purified using flash chromatography (SiO2; 50 % toluene: 50% petroleum 
ether) to yield the title compound as an off-white solid (532 mg, 24%). Rf 0.64 (100% 
toluene). 
1H NMR (250 MHz, CDCl3) δH 4.03 (s, 3H), 6.93 (br. s, 1H) 7.03-7.34 (m, 5H), 7.46 (d, J 
= 8.0 Hz, 1H), 7.67 (dd, J = 0.5 and 7.5 Hz, 1H), 7.87 (dd, J = 1.5 and 8.0 Hz, 1H), 9.70 
(br. s, 1H); 13C NMR (62.5 MHz, CDCl3) δC 55.8, 99.5, 110.9, 111.8, 119.8, 120.2, 120.5, 
121.5, 121.8, 128.0, 128.3, 128.6, 135.9, 136.1, 155.7; νmax (film, cm-1) 3443, 1577, 1463, 
1435, 1308, 1232; m/z (CI) 224 ([M+H]+, 100%). 
(2-Phenyl-1H-indol-3-yl)methanol, 223a 
2-Phenylindole-3-carboxaldehyde (300 mg, 1.36 mmol) and NaBH4 (103 mg, 2.72 mmol) 
were stirred at reflux in ethanol (10 mL) for 1 minute followed by stirring at room 
temperature for 2 hours. 1% NaOH (10 mL) was added to the reaction mixture and the 
product was extracted with Et2O (3 × 10 mL). The combined extracts were dried (MgSO4), 
filtered and the solvent evaporated to yield a crude product which was re-crystallised in 
PhMe:EtOAc:petroleum ether, yielding the title compound as a white solid 133 mg, 44%). 
1H NMR (250 MHz, DMSO-d6) δH 4.81 (d, J = 5.0 Hz, 2H), 5.10 (t, J = 5.0 Hz, 1H), 7.14-
7.28 (m, 2H), 7.48-7.53 (m, 2H), 7.64 (t, J = 7.5 Hz, 2H), 7.80 (d, J = 7.5 Hz, 1H), 7.92 (d, 
J = 7.5 Hz, 2H), 11.47 (s, 1H); 13C NMR (62.5 MHz, DMSO-d6), δC 54.8, 112.1, 113.3, 
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119.9, 122.6. 128.5, 128.9, 129.67, 129.71, 133.4, 136.8, 136.9; νmax (film, cm-1) 3488, 
3183 (br.), 1638, 1491, 1452, 1392; m/z (CI) 206 ([M-OH]+, 100%). 
2-(2’-Hydroxyphenyl)-1H-indole, 209 
1-(2-Hydroxyphenyl)-2-(2-nitrophenyl)ethanone, (105 mg, 0.41 mmol) was dissolved in 
methanol (4.1 mL). Pd/C (10 mg, 10 wt.%) was added and the flask evacuated and 
backfilled with hydrogen (3 cycles). The reaction was then stirred under an atmosphere of 
hydrogen for 18 h. The reaction was filtered through Celite® and eluted with methanol (10 
mL) and the solvent removed in vacuo. The crude product was purified by column 
chromatography on silica gel (10% EtOAc in petroleum ether) to give the title compound as 
a pale yellow solid (62 mg, 72%). Rf 0.39 (30% ethyl acetate in petroleum ether). 
m.p. (EtOAc: petroleum ether) 170-172 °C; νmax/cm-1 3500, 3425; δH (300 MHz; CDCl3) 
9.22 (1H, br. s), 7.70 (1H. dd. J = 1.6 and 7.8 Hz, Ar), 7.66 (1H, d, J = 7.8 Hz, Ar), 7.42 
(1H, d, J = 8.1 Hz, Ar), 7.26-7.11 (3H, m, Ar), 7.04 (1H, td, J = 1.1 and 7.6 Hz, Ar), 6.91 
(1H, dd, J = 0.9 and 8.1 Hz, Ar), 6.87 (1H, m, Ar), 6.0-5.0 (1H, br. s); δC (75 MHz; CDCl3) 
152.0, 136.4, 134.8, 128.9, 128.4, 128.3, 122.2, 121.5, 120.4, 120.1, 119.1, 116.6, 111.0, 
100.2; m/z (ES+) 210 ([M+H]+, 100%); Found 210.0920, C14H12NO (M+H
+) requires 
210.0919. 
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5.2 Appendix II 
Shown below is a generic example of how the calculations were performed to 
obtain the desired cell counts needed to seed the glial cells in well plates from a T75 tissue 
culture flask. 
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5.3 Appendix III 
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5.3.2 List of conferences attended 
1. Poster presented at the British Neuro-oncology Society (BNOS) conference in 
Cambridge (July 2013), 
Prabhu, S., Snape, T., Lea, R. and Harris, F. (2013). Cn-AMP2 from C. nucifera is a host 
defence peptide with anticancer activity. BNOS, Durham University. 
2. PhD project nominated at the Royal Pharmaceutical Society awards in London 
(September 2011). 
3. Poster presented at the British Neuro-oncology Society (BNOS) conference in 
Cambridge (June 2011), 
Prabhu, S., Harris, F., Lea, R. and Snape, T. (2011). Towards establishing the effects and 
mechanism of action of a series of substituted indoles in an in vitro chemosensitivity 
system for glioma treatment. BNOS, University of Cambridge. 
4. Poster presented at the UK-Netherlands Joint Symposium on Antimicrobial peptides 
in Dublin (March 2011), 
Prabhu, S., Harris, F., Dennison, S. R., Radek, I., Lea, R. and Snape, T. (2011). 
Characterisation of an anionic antimicrobial peptide isolated from green coconut water. 
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modification and applications. University of Durham. 
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6. Presented work at the 4th Annual Retreat of Brain Tumour Northwest (BTNW) at 
Preston, England (December 2010). 
7. Attended the British Neuro-oncology Society conference at Glasgow, Scotland 
(June 2010). 
8. Presented work at the 3rd Annual Retreat of BTNW at Preston, England (December 
2009). 
9. Attended various medical seminars and meetings organised by BTNW across the 
UK. 
10. Attended the British Neuro-oncology Society conference at Hull, England (June 
2009). 
 
 
